var title_f2_45_2768="Toxic shock syndrome";
var content_f2_45_2768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Toxic shock syndrome: desquamation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwATYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjPiteJbeGDEzENcSKgx1x1P8q8DYsxkbO4LySeK9G+JesNq2ui1g5t7QmMd9zfxH+lcTNbrho1HOMk98+lediZ80j6PLaXs6eu7KVuxRW4+8KuNs3BY4yrAc5Oe1RyWghRSGy5+8npSs8hRQMcHmuVs9VRvqie0jd5gMEZyBjp0qVlHmeXlQvTn1qtGx4OGDdsVcttjECX5B7jIzU3HJW1I1tpmyU5I60rxmMFSR5gIzg5A/GtB9ibkiw3cNjg//WqvGoyPNwAT0qWxxd9SJCd+CMnuKsAsc+W5A/u06f5flA+YdKgicHCB1BLce5pq5MtSC5dYwAU2svXJqiLlixAY5znkcVeuIcOiSSK+c/hUcsKQkFiHL8ZI7DvWiJdrFLawRizZH3iTSFyYSAAcnr3FPl+dTgtjqc9hTXkyhjQjYepxz+dNbmc7JFnSNNuNW1W2sbcEyTMFz2Udz+VfS2mWUWnWEFpAMRxKFHv715X8F9LMt9c6pKMiNPKjJ9T1P5CvXq9KhG0b9z5zH1eapyroFFFFbnAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWb4ivxpei3d3/FGh2/7x4FaVcJ8XNQ+z6HDZqfnuZMkZ/hXr+pFTOXLFs1ow9pUUTyRp5WmZsne5OSPU+9RmZlUrt+YNwT1FIP0PpRIg3AsxJ714sm2z7GlTSQqA+b91drcZPrUjeUIWBTr90r2NN+edgu0DA4J4AqbYEcLKcE9SpyKg1KzqYceYME8AetPZd0eFB254NWlgh8vfvOM9ev6U6JHdlkXBG7oBj9KAvcbtcR4I6Dse1KYZvJV0Csq/nVrbDuxnnrzzTRcNwAxTaMYUUrISk7aDIYpBEWlwVJ4Qg7iajnRVO51wUHBIwVq+jxqwJkkYNz05U/WszUt06sVDKgOfr71d7GaTb1KizRpcCaRS4zyKsXSRmKMMG8lgWUluOeuP8KoMd20EjA45qQ3Kvbi2dRhAfLKnGM9SfWqgx1FsyC54OEkLBB0PT8D3qsEaSRBGOScYA/Wp4x5sTbY2bGCSB0rW8M2ZvvENlbgg7nHOOcVrTjeSRy1p8sWz2z4e6Z/Znhi1jK7Xf524rpabEgiiRF4VQAKdXqpW0PlJy5pOTCiiimSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXinxRvmvPE0kQIMdsojU+/U/zr2e4kEUEkh6IpY/gK+b9Uumur+eZ87pZCxPXOTXLipWjY9PK6fNVcuxGpG3O3J9e1SRxNITx26UW6HHzEBevNWQBjgEn0ryGz6ldis6kMMnJ9qYMK3AX8ecVa8tmwQhI5qNIDyccd+aaYxkfOVUEMcYNXIQ6Dao49TQse3aAPmqwMBSWJxSb7AReWGCs2Rg8kD+tRPCzE7Sc57jrTndT3PPHPrSsFEZPbt7UBsRklZGAYbh6VXmYhejEdxU7LltxXjHNZ1yzM5APHtTSFoxs5VupCkdABUaTwpHLut0dm+6SSCp9qQxNjdyMDvUSoVZJHZCoPc1rHQynqWEmeOEKXUsDgqOuPrXafCS1M/ihppDv8qMsD9a4MtsBUOGQnI4xXr/wX0/y9NuL1gf3h2Jn0rrw6vI8vMJKFJ+Z6VRRRXoHzgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGF43vfsHhm9kH33Qxr+PFeAL80h6sw7CvWfjDdbNMtbYNgyOWYD0FeVWrfOSvJPAJ4FedjJa2PfyqFoc3csxR5jyBjHduac0cuwK0pDL1x0xR84XYzoEppeNdoDg4IzgVwHtoX7OpQBpXb6HAxUsdgm0MsrAf73NPDKNuMsT7dqnilYLztHvS1C76DFtAq53OW9C1RTW7j+IhMdRzzV05kYlJCcDkYxUUityC7Djvx/KgFJsoyB0xsbJ9xilDzvHgqMDripmjH3mY5B6DmnMUZDlhyelVcqyKptyAxz83b2qh5bMxxIxweprSnHzFYuMDkAVS2lMkk7e/HNCY4rQglQM+1M4Heq7xfOAcdanDEkHBUf3ieaiYnzDtPI9D1rRGciJYQXwN1fQvw7tfsnha1QrtJ5NeEabD9p1K3jxndIBgCvpLTIRb6fBEoxtQcV34WO7Pn81ntEtUUUV2HjBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeP/ABZuw/iCKDqIohkD1NcZBbFlxvEann2rofH8wuPGN8FydpCcewFYsEPIDWpbn7xPIFeViXebPpsCuWnEkjggUAPPuI7kirEcdtvJEic8ctSRpbgt5tngDr8uashdPdjiKPpjO3Fclj0OYQBWQFJIjjjtSqGZBhk2+wqJ44hD5KCDBbIJQA1RfTZlLMiNt65jlIzT5QNVHdfvEkdMCo5HVgCzuB6YxWSZXicFpbpAeOQGxSteR/Mr3fI4G9McUNGsIFyQMSdjE9hhqgCtuwxJAz3qHEMqZ8+L1681WFspBYSHnsG5osapF1yfMJdvmPqc4qpcohHJwO9RC3US4LH3pXt4Q+STtGCTmgfLYYXhCABhnPc1FIUAALYA6nFSOIlcLHjHY4qIqJW4OM9TmtImM0dP8O9PF54hiKLlY/mz/WvfFGFA9K8y+DdgqR3t1joQik16dXq4eNoHyeY1Oas12CiiitjgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApksixRPIx+VQSafXDfEfxGtnbHTbNg11KP3hB/1a/4mplJQV2aUqbqyUYnmmsTi51W7uGdcySsxxx3oikkGAs0R9sdahgDZJK9e5GTTpQQQVRGOO4715E5czufU0qfKrF1byaFsNGkiEYO084p1tqFl5im4URHPSSPp+NYkssir8hWMjsAalg1KQgJcRJMnTkVFtDfkZuzWlnOolhOQT94LmorqwMalobny2PoMcfSqSiEv/oUk1sTztDZVqlW/voDlo1mj6YHp60cpS5uhn6jJdQsoJSYH2waqC9tZCBODG3fcP61vz3dleR4fMVwOQDxWdqOmRG2Mqcr64o0sb05JaNWKxjtZFARo2H4VC1vBuzGcH1zVKawCnDAqPVOKli08Mo/fy7R1+alY2T8yw628ZJ3c/71VpZbfPMozmo59JiErBZJCD1yTzULaVCCAqcHrmnZFJeYsl3aFgFk3EdTmnG9gRh5b7jnPHOKiazjyflHBxyKW2sY1lyyDH0q42MakND3f4Rhf+EZLggmSQscdq7ivMPg7cCI3dnu+UhWC+9en16tJ3gj4rGxca8rhRRRWhyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWT4l1qHQ9Na4m5c8Rp/eNJu2rHGLk7IzfHHiiLQLMxxMrX8o/dp12/7RFeOS3ElzctLPIZJZDuZieST1o1W+uNU1GS6umLyuc+w9BTrRFTmQ8+wry69bnfkfS4LCKjG73ZaROnyHP5A06KAsW3IQfdqnUF8ADOPbmrCW2dpiyh68jP4VznYtDCu7JgGMcvvtJ/SmxWzqp3IpUcg4rYu7cgHcvPfPSq8AyMOmPY+lNM1TujPTGzaSRtOcEZzQ8WXDIxAb0NWlQCWQkcg8Uj7V4Pycgg/jS6msSpLarIDGWw3UEH9amtJZo4xbXOSoyEfNK0ZFwQ3IHf1qXYHi2EDaScN70FvValS7hJjl34EkZHA7jFV7SJ2TknGa0E+aZUf73l8k98VJZqBGxIOM0MtOyKEihDkAFhyM04xR7ckdRkYqxJEN5zwSelPnCRgIxI4H4UrlNmU0GWPbngUkjBJMKMt1OKtSAhsAZIplzGA6gDHTOBVJ2ImnLQ3vh9PJb65A2/G/ggd690U5APrXz5o0n2W9t5c5IcZ7d699sZBLZxODkFRzXpYSV42Plc3p8tRMnooorqPICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKjuJo7eF5ZnCRoMlieBQAy8uobK2kuLqRYoUGWZjivFfFmuSa/qpnAYW0YKxRnsPU+5qbx14ll1q72QOyWcR+RP7x/vGsSzy/Rs+/avNxOI5vdjse7gcFyL2k9xII13fNjnoc81eUFQhO1seq8Ughxg4yy9BjJq7CrTfORwemRXFc9bzFiZSVxMucf8s1xUxJ8lmSYZXqAgyajhhdUAUgYNNZG3tlmyKu5NtR0scUwZg+PT5qow4DFCxyG44yCKsbpmXai98H6VAoEEoLeuCaVzWMQulUMMgeh46e9Z1yc8A8g8dq2LhcqSGwW4BPNZN0GEpYMM9SelK5tS1FuPlVCWKsVB/OmF3ZFReh5NT3ADJCpz9wc1Xk4XoPbjmhsuIgwXhbu3qetTiQiJI84Oc/WqttycsSVTLc96uWUTSTF3HyZ4zSbNWktWXIYgpDzEn09qpXq+ZMqhQc+lXp5wI2QYP1qvYoJbo7ycKKDNN/EylLDsByST3zSncFBIOSBwRV68RQwVSCGP5VHdKVRMHauO1K4N3KUqsiE9emfavXPhxqf27RliZizQ/LkmvJHAbd1x9a6j4e6r/Z+sxQs37m5+Q57EdK68LU5ZWPIzOj7Sm31R7FRQMEcc0V6p8sFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRTZHWKNnkYKijJYnAAoAHZUQu5CqBkkngV5F4/wDFh1O4+w6fIRZoSCw/5at/hTvHXi99Tkey09itipwWB5lP+FcXCOfmIOD0NediMTf3YHu4DL3/ABKn3E0aglSduatWUG27MZcBW5Ax0NRWi5lKMp3A5yO1aCR4ckffxlWIyeK4L3Pa5UtC+lvKNoGDkdRU8dsVRlcYBGfarFtMnkI+4ZKjI7k00bpiXIKqBkhcY/GtEjnu9iAxhZwgYAMucc4471XIZJGyd/GOuKmcNLLEyseMjOO1Vrr9zKAzAjsfWkzSKu7Ebybn2jcPWo5FYg8DbUzBpMFRkYyOKZtySM9OwqDZJIdGMoOD06mqk8Qk3b14z19asNLtQM3D46U0SKYgG+YAcCgqOmqKbwhPLBY7B2PWoWBaTfgBR61bDeZK2RnAwAKguspkKw/Chs1jqyvbrh5Bj93kbue1XIZN7Y4Vey1TtgNjbmOGP54q5bcsCRgjoKDWWxI0W1DvGSeetT6fEFtmfjdnkdxTJyqRqerdkogkYx/IMA9QPWgyesRnll7pSx4HPsaS/wCCSrAA9M9quwxAZdwSehNVbggnoCB6elLYV7sypThjyPwFRxStDcwuhOY2Vhj61YnAMjFRgDnFUhjcewzg1UHZmdeF4n0Nod0t7pdvOrA7lGcVfriPhbf/AGnR2tyctC2Pwrt69ynLmimfE14ezqOIUUUVZkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeY/FDxKfM/sizfAUgzsD1PZf8a77X9RTStHurxyP3aEqPVuwrwJ47q/a4uyhdQ26SVugJP61yYuq4x5V1PTyzDqpPnlsvzIIhIzt2NXLeF/NXKgAjPrU+j2RupwWOIlyzE+grVs7UyoSoAycr7V5Mkz6luMNClbRFLkE8bh36mrd1ExjDpkMvYGtI2KhEmIyVIbrimXzCNG2csOfm/rVKOmpi6l2rD9NhP9nowwDkgj1/H0qBp3inKkKV7KgpNOmaW2aMMVUN+PPWlddhyqlVxz/eNX0It7zuRPJJI6lMRgHk9abLEvBILE85NI4ZhiPAA5JPak3sSPm4xzxUGyj2BpPk2g45xj2qGTHmDk806RQr9j7jvUc5XYvTHWki7DXIJ3A5z6d6rncThgBzSiQ8AdAe1NIk3ZJximNIkUpCjjnefQ1U2O2W5IFXI4YyoaTO/r161JMq+QVjHzMQBx1pFxdiH7OVs4lAIdhvqSKIspD/ACkfeq+IeFAOSoA5NQuMSOy9R27GhiU7lVlV5FOCRnaMc1chiw2MYGeoqJSJJztGFQZ/GrlooHLnDZ/KgUpaDZVKkjqpFRTJlMqB0xip5tu7Awe4zUDln+UHGOuKGQmZckaoGDkk9eOlZkkYWRixJzzj09q1btW3kKOPWsyVMoMjLHg0o6GkldHa/Ci8MesywscLLHwPcV67Xg3gy4Fv4lsj0BcL+de8L0r18JK8D5PNKfLVv3FooorqPMCiiigAooooAKKKKACiiigAooooAKKKr6hdw2FlNdXLhIolLMTRsCV9Dzr4t6rlrbTYzgD96/8AIf1rhLMbAUZnaFudqt1qXVb+bV9UuLucDMjbgP7q9hT7GMmZRwuD0xXi16jnO59bgqKo0kmatk6BymwLG+CT6YrROVU7UHlHoAearyIIVT5QWyOMZyKaZDIrLGSVThyO9Zm2ktUTQztLujLDaBn2qpfuDEckEY61G8MvDjciDIxjg+1VJnb5jJ07AcgGlqbRgm7olsZzvKgFAVyc9c1baQ/wgsfUms7TQZpHDnGeQAM1dkjhTBZySOeTT1KmkpWJMAjAcZ7j0qOYhSMtn29aha5MgwgwccYFQAyHrE+enJxSbKjBlmQkqdvBxzVNnTzCXwSBgZqQQ3D8HCrzx1p0NsqBXcZzyTnmkh6IgUyEDCkZ/CnwxSMoZiMbvxq6Yw0Yz1qe3QENyBjjBFUiHMEgi24RB8vOTSKnmzlQAAq5z2zVpl2rkDjHWmWagwu+Mh2/SgzUtLgy/JuJxxz71VfZGwLAY78dasSEDaXyMcCoZVMjBDz3PNJjj5leOFgxkX77c47c1ZRiU3Z5zyKlj5DryCtU0m/eldpyaWxd3IllJLnkMfYVGyOpIBK+p6ZoBwxUDLHvnpUkwCjHJU+poDbQzbsMiEKcHpWeRh8bsMQTx6Vrsu4uP4fWsydQrnkZ9qRa2G6U5i1W3fqFlUgD0zX0NCwaJSO4r57hzHtZuoOfxr3rRpfO0y2fn5owTn6V6WCe6PnM4jrFl2iiiu88QKKKKACiiigAooooAKKKKACiiigBGYKpZiAoGST2rx74geKjrF3/AGfZFvsMTfM6/wDLRh/Stv4n+LFtom0jT5Va5cHz2XnYv936mvNICANh9fSuDF17e5E9nLsHzfvZr0LUMZ3KFzk9eK3bWGOKAF0y5/zms/T1ywJ5HqOgrQaQSJycAccV5t9T3Wug6eR4jC7LmMnA28celN2nzGIUAN2HWo5pwYBEybgMkAntT7O4zHIsY37MDce9VcfwxvYkuy0UENqjb+dzZPAqOKyaRdrYUH+I8itO2tlVS8uCxHJNSNnAKbjH0HHWrUbmPt+XRGVb6a32kKGdwq/w8D8TVq9tZI4VaNYxx0UZOKvpcRwOVi+Yep70XTCaHCElcZOBjNEopDjWlKSb2MFIHK/e2470EFGXDEse5qeaIoAQ20jrzxTIn24aRc554rI673IpJGU5I56YqwqKYgXHzDkAdqrM4kuiSCMDIB71OHwASCB2JoJkOldUjJI68D61ZiiVY12sXbv9aoeYrywkbcBskEenvVszAgnaVf1zxVXM2hbkvjYec/LV+Nk2lNuAowAB6VSg3SyK0gGUy3H6VaTKxsSGJPNV0IkuhBcrxgHIOMY7UkS9T370l0CE3dAPSnRlIoNxfqKkroLMi7TIOCB1rFlfe7LGMkn73pWnMzTEKnER65PNRCFVACgBcetJu7NKb5dyqmQqZ5O7qf51MQHYntjoPWnAqrbSvI4FCAK7kcnPapLbuK+PKwq4PSsW5UluOoOOlaUs3AwvBPI96pzvhD8uSDzRccI2KhiZupJA5Ne4+Ezu8P2RPXyxXhzFkAOSR0IFe1+CXV/DVnsbcAuM5rvwO7PDzpe6vU3aKKK9M+dCiiigBDRQ2ccY/Giob1AWiiirAKKKCQBknAoAK888e+PItOWXT9Kffen5WlHSP1x70/x742isrWex0qTfeMu1pV6R/j6143GHuTuk5YZzXDicTy+7E9bAYB1XzzWgDzpruSSZizMc56nJ71o24zJzkucAmoI49hA45/StqysgIhISDnoK8ttyPpVGNNFyBRGoU4I9B1P1p886eSAn3B1wOpqt9xwUPGe1Vby5DSkoflU8D0ouKMeZk00yAAvy56D/ABrT0srFLKH5YnIHasCwXz7xd7DA5Peu70jw5d3Ua3KIqxY4B+9WlGDm7I58ZVjSVmyJg6pvmA2ddnofeqst2XVVLYI6CrGpq1uqqzMCrYZTx+NY6Trh55WBSM4yBk1tKXJ7qOGnFz95lsZUEbi+f4ugqxbLJNCQTz6E8VTgvmnV/sx2xNwVYcmrdrevayDzLYFT1w2fxrBO8tTuUJKO2oNYv5ZzIpycgYqs8B3EscAcAe9bSSpNCHCr24z0qhOYVlddpVm6giqkkiqdSTdmZhiwwPO6rJXfCFTB789qbJt3hRk5H3uuKR98Y4O1enTrWZtJ3IomVZ/ufKBwQOhouAzuu8kDPUGhV2gFycHnpzRb4mmKEjAOR9aEG2pfWJocAsST6/yqVrnCnzgCo4yO1QeYkW5ZWwy9PSqriWZiM4jPfHWm2RGHNuXJpw8gSL5jt69garLC7t8/zdutRuo2BTkdOhqWEnJ+Y5FItR5VoSy+WTj7o6cjimOoC/KF2kVHKSNzb8j0qQxqIc5I+lArWIo/u9S2OB7UizBA6KBnvmmxlwSvBPUYOKqzT7SwVgST9DQzRRuya4KbdxXH0qg7krkYPoAMYFK0skpwsZyD37fWmS27Lgs+c8DHepNFHl0ZSkukGQAdwODxXs3w5cP4VtiPVs/nXjUqAcuo3jjrXq/wul3aNLHn7kn5ZrtwTSnY8bOYfub+Z2tFFFesfLhRRRQAUUUUrAFFY/iLxDp3h+187UZwpP3UHLN9BXj/AIq+Kt/qDm20dPskJ/jz85H17VlVxEKW71OmhhKld+4tD2fVtasNKiLXlwiEfw55P4V5f4q8dXeqFrTSFaOMkqWHU1wOmRXWp3LS3csjp/HIWyc+gzXS2NvbQt+7XYc85PWuKeKlNaaI9GngYUXeer/AyrbSpJpGNxMMrzxk06LTDHd7AcqT97HWtv8A1cwKAFTzjNSBlh/eODg9CO1cbSPUp1ZLYppaQRh1Byw4+hqo87wKNxJHQj0q3PcRNP8AL+Paqcsccq5QsAB371Lt0OmD/mGyXIPzDv0NZl1MFJVenrT5gYWIOcN0rpvAXhKXXb77Vdoy6fGeSeN5HYVVOm5ysi6tenQg5yehsfDfwt9sjXUrwERt9xCPTvXrEaLGgVRgCmW1vHbRCOFdqjtUtezRpKmrI+PxWKliZuT2OS8U+F5davo/KkWGDb+8buTngD/GuT8U+HJtEtYZI5PNjZwDj1r1msfxZaC70G7U8FU3g46Ec1FXDxkm7amuGxk4TjFvQ8YVymJINwPVgB1rQivWdcuoLY7jkVUX5c7V5z3NX7aFmIZR8wHB9BXkdT6265bst2UzBxNuULn5gP8ACluGEkm3bnPfPT6VIIkmh3MVV4/lY4wagZMAoi/vD6daZjdOVyvgROUcnJHBz0PvSDLIEZgQG79KbdMzgF8hu/v9apifPygkc9TUm0YuWpZup1HyA5J4xSwmRQFjw3P3qjhtjJKJH6ehPWp0YxzeXxg9D6GmhtJKyJliQkvKdzds9Kl3s0ZXjb1pCrPjoRj86hmLIrFm4PaglK4yTBIDD2HtSocZ4wM9TVU3O/5h24wDR50kuQV2g9zyaWxbiyaWZOmRgcGqrTzSHCAqOOSOKQxANtOSB3qaPcCQSO2M0FWS2GRCeM4LkMx6jvUsduqknH1J5NEbMz4Y5Gc1OzK+OT7CkJtkbMoHIUBeVPrVa6k2qCw6jtV3CyIxcfd5ANUbpFduc57CkEdyhI4KgNwG6Eiu9+E1wwuL6A5IID159dbw+1hnI6+grpfhfI0Pidfm+WVCpPrXRhXaojjzOnzYeR7NRRRXtnxgUUUUAFFFFAHgfxltJ/8AhJZpG3BHClSe4CjpXB28OMeZ9wYyO9fSHj7w0viLSGWM7byEFoT2J/un614KLCQ3TW7qY5Q21wRyMda8jF0nGfN3PosuxMXS5HujejkjjgVI41RQO3TFLv3Zw/U5xUUq7f8AVjgYHNQlyJhHH8rYzjHauRy1szamr6mjbykEjj2q1HK44YK2eOfSs3znAAEQLe3SldLl8Ejg9Fz1prXY106k86pnIwfw71DCpb5V69TVnT7a5nkRDErF+Pl616D4X8GQ24W5vlzIeQnYVrSw8qrsjKti40I6mH4X8E/bSl1fjCZBCHuPevULW3itbdIYECRoMAAYqRFVFCoAFHQClr16VKNNWR8/iMTOu7y2CiiitTnCqmrOsel3buMqsTEj8Kt1R1zH9jX27p5L/wAjSlsyofEjxE3CB0JxkcHPrWlYXceeFLMecCsS5iHy5G7OM4rZ0+NGChCATzXgvc+4aXJqabSSTfeAUY6dCPxrMubhreXagGc8kDJrfhUNHyQx7nrVK5giVgV/EEc02YU5K9rGQiysx3yKQ3JA7VC0UUbjOWx1qeTbHMzOMbuw71BNdAyAooyO1ZndFPoWYZWJCqQvpU2Nkm4HnuaoR3SCXPC56Yp0t3nIVWOeMdM1SE4O5ovKix9MKBnOOaybqeadgsIIjb+LFWk8wgGTp2ANOEgVMghSemaVwiuQo2sZgzvblud1TCRhkYDEjjP86WbJAORgd6WDhiDnd60im76iK53HADAcEGo5yVfCr0Hp0qx0YmM//XqOYFiQRg9SRTegLcbA5AJPU9KdKxwu0DI4zU9uihcSdcfpUF6gRlKHI7VIXXNYX5yODgE8moLiV0IPBAPFIbrjttHWovPDBmUgkgdaVxqL6kFy5kZsAAJj8RWl4WmNt4g09wRzKo/Pisy4IjU7hk9ABz+tV7SWZL6F2+UxsGB9MVcHZpmdenz03E+kaKr2Vwt1aQzocrIgYflVivoE7nwLTTswooopiCiiigAriviBoMU1v/aVvEqzJxKyjkj1rtaZNGk0TRyKGRhhge4qKkFOLiy4TcJcyPCTbHcOMkV0+leAbmaJLp7qHMw3cqcgela2peDpo7rdp+2SAnO12wVrsdKikg0+CKYASIu04rho4VczVRHbUxclFezZ55r3hmHRtPWRZhLcs20JjAx3NZ1jpU19MFij/L+GvUr/AEy1vnVrmPeV6ckVPbW0NsgSCNUUegrV4ROV1oiVjZKNnqzK0LQYNOjV2UNN646Vt0UV1xioqyOOUnN3YUUUUyQooooAKx/Fs5g8P3ZX7zKEH4mtiuZ8fSFNGVR/HIKzrPlg2b4aPNWivM8sljJJx8uelWrONkwVJJA5FK0YbbuzyKsWMLbSVZiB614S1PtXK0TTtLhSiBQMnqD6028ZZSeF3HqPSq0kR3IUfn0oXdwXAJ/WqbMFBX5kU7uHcMdyOfpVB7QGRTnOe4rXIbzmL/dyetQRxBmIPQ9DUXOqE2kZ4tg7BU6j+IitG2tlTBbBbHXvTogFkIXpnAJqwhVWPygkjH0qkKdRvQb5Ksm44I7YqnNGruWPAHHXirsaNxk8ZqK6U8lTgdOnFDWhEZalV4iQvOPY9KhuUIkVVGC2BirRBPJOV9SKiUkuuCDg+lJGqb3JPIZcg4yOn5VDMHiXBYEHqTVh5CrHccgc1l6hc7jhSOKUmEFKTHS3AQL8+SR0J6VSa5DkqX4HfNRXDLI2T27Cl0TS7zVdREOnRb5WGck4UD1NOMXJ2W5tJxpx5pO1iCWTMmBuOf1rTsLVB8zMHcLkqOg/Gmaray+HNTez1KIC8kTejpyjL7VBbTNPvjyqrIM4x0onFwdpIUaqrQ5oPTuWpwrRqhkAVQchRnmqSoEIKk7f4fetNE2xkZGB1B9Kqyo4QBlAGeMDtWdxXurHrXw4vBceHIos/PCxUj0HUV1VeV/DPUDa6p9kkb5J1IA/2h/k16pXuYWfPTR8RmFH2VeS76hRRRXScQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcl8RHH9n28eerliPUAV1tcD8RbgNeQQbjhI92PQk1z4qVqTOzL482IicYhAbHqa2LDCRlm4IHANc60sqyD5d+Ou2tHz90O5HKsByM9a8WO59fUg2kX2lQsGGB71DdT7SCrAkHvWV9tcEAqMEnkVBJcfMWzlcZ4pu7LhR1NC6vVZlIp6TqAqnhvpWZHJHKVYEewp8ZIkPBPpg0jRwVrGtC6l8g8dzj+VO3rv2IMDPzGs6NmabcRj0APerisFXcnVTz71WxlKJpCNGBYDAHbPIrLvrpUYgD5abLqIAIXgN1561k3Fwx688/pSbbClSd7stNqIEeM8fzqGO6CEu/Iz1NZk0oIwcZ68VLBa3FywVVK4/iPQU0jZqEdy3dX2eVHJGTWTNdjHJAxxWiNOYuRvZynXjjNQTWIU7WXA6npScTSDitEZb3TBSwO71Fe9eA9Eh0nRYZQM3FyiySN9RkAe3NeB6lCqIfLfGPSvpTQXD6Hp7DobeM/8AjorvwMVds8HP6klCMVszjfjDpH2vQ4dSjH7yxfc2O8bcH9cV5jbosojeBjvyTgV9BavZpqGlXdnIMrPE0Z/EYr5z00ta3D20oIkhcp05yOKnHQtJSFkddum6b6fqbqtviUkAn0/nUMrboQ0hLDlDjj6VIzbJCzjI+8gHOfasw+dOrsw2Jn7tedY9uKTLGl3ptLpLgNteJgRk+lfQNhcpe2UFzEQY5UDg/WvmqZBFJkcsD9TXq3wn1ppYH0ucn5AXh3HkDuv9a9DBVeWXK+p4edYVzh7WPT8j0aiiivVPmAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8l8Z3hudbuyoz5Z2Aew4r1a4lWCCSV/uopY/gK8Q1OWZvPmjUPK2WAPcmuDHS91RPYyeneo5EturBBhct3NTywq6A7cEUzSd8luhmUpIQNwz3q86AI4JJHQcV5qR9BKVmc/eQsiFl2gHjA71RRyshVt3HWtifBR1PQsSPWsq0spL3UobWEkNcSrET7E1SV3Y6lUUYNy6D9P0y81e/EGkwmR0P7x+ij6mtHxJpmoeGIrVryMOs5KqY2zgjnFexaFpFrotglrZxhQB8z4+Zz6k965H4yRb/D9pL/zzugc/VTXfLCRjTbe54MM3nWxMYRXut/M83tLma6mwnyFuhNaRjmERDzhX6bFQsfzrJs2O5Qq5z1HrW5HIGWJW+UKe+eRXEke9PTYzJ7dynzSMR9AOazNSEsDbRIScYBIxW/fuFYqORnGQaz9exIr7gBhMZz7UktS4zely74U8IXGqeHrrWJndRHuaKPH+sCjNbsT2cdlshXaoX5ADndxwa7/wXsbwhpWxAqm2XgDjpzXgBlvNJ1G/sPPkXyZ3iKjp9413VYKnBNHz+HqzxlecZPZ6HRi8FtcOEQtuPIY9/QVT1O6kmjV9rKAcYNVIWkJDbjn19KjuUkkjbMjHPYmuBs+hhTSaZkX828EdSOoBr6Q8ESifwjpDg5/0ZB+QxXzpJblcnbjIx9a9m+DN80/h2azlOWtJcDnna3I/rXZg5WnY8fP6fNRUl0Z6BXz/APEWyOleN7uRQEjnYTKeg5HP65r6Arz/AOL2gHU9IivoE3TWhO7HUof8K6sVT56enQ8TKa6o4hX2eh5d9oNxGPKfG3j5RzzSFbjeoMZ2gHqabpIWLeqjqOK2ppP3YwcljgH8K8U+xvZ2SMVIOrMct3rS8P3k2lajb3K8GNwSfUdx+VUhG2Tljg8gmnoHLEdBimpWd0TWgpxcWfRFvMlxBHNEco6hlPqDUlcl8N9UF5ov2V2Jltjt57qeldbXvUpqcVJHwVek6NRwfQKKKK0MgooooAKKKKACiiigAooooAKKKKACiiigDF8YXIttBuOcGTEY/E/4V5bFtdee3euy+JF581rZqwxgyMM/gP61xdug4JJyTXkYyfNUsuh9LlVLlo8z6mnAiBVCKMkZyKLmULgnB44yfajPlRKAQGPAqnczIT82MAZNcx6MI3ZRmTcHxngYAHvWl4CsjdeLrduqW4aQ/UDA/U1lzyAgEHHP0rsvhNb721K8I43LEpx+J/pW2GjzVERmFT2eHm/l956LXIfFOMSeFHyM7ZkP8/8AGuvrmPiOM+Fbj1DKR9c161X4GfKYR2rw9UeNWcgBKBfut3FaILhC0UjKD8pANZ0KbJSE71rWqgkEjLevpXiH3b2uZ00Upb75Gep9DVPUIzJE8buS3PNdDOqlGGcjr9Ky9SYFi2Bxzkd6SY1K+h7D8OLsXngrSpBkFYvLOTnlTj+leLfESL7J8QNWQIR5jrIB9VBzXqXwauPN8JPEesNzIvXscEfzrz743wGHxpFMM/vrVGGPUEivUq+9RTPm8D+7zCcPX/MzrJBIqjkH25q3dQiM7c5DD8qg0IB4zJnjHOOlX72HbEGAJXPOa8yx9Jz+9YyJDt3BccY7V2vwbujHrV9bdFliDge6n/A1w875zt5B/wAa3fAF4lj4wsSTtEjGI59xj/CtcO+Womc+ZUufDSXke8U11V0ZHAZWGCD3FOor2j4M8b8c+EW0e5e+s9x0+Q5OP+WR9D7Vy6vtjCRsSO1fQmoWsd9Yz2swBjlQoQfevAdQtG03UprW5BBifaT3ryMZRUHzLZn12UY514OnU3QLGWTlSOxNVhIIjICMgdz2NSXN6hg2py1ZEgkkRizEccqDiuSyPZinJancfDTVhD4qigD/ACTqY2Ge/UfrXtVfMWkyyWF9b3cB2yowYH3FfRug6imq6TbXkZH7xfmHo3cfnXpYGas4Hy2eYdwqKotnoaFFFFegeCFFFFABRRRQAUUUUAFFFFABRRRQAUUVQ127NlpF1cL95EO36ngfzpN2V2OMXJqK6nlfinUI7zX7iRnJQPsU/wCyOKoxyhjiJ04PSqc8atKd/OeSaktbdGcKw2n3GK8JvmlzM+3pUo06aj2NpniaIF5AXA/hrOlaIhwXHPHI/Wm31sUAZM4xg7T1rIuVkPKMSD/Oh7m1Kmmrpk17JldiMMetevfDyy+xeFLPd9+YGZvx6fpivGIUe7nhtkH7x2Cc98nFfQtjAtrZwW6fdijVB+AxXbgY6tnjZ7UtCNNdSeuZ+Ih/4pa55xll5/GumrmPiP8A8irc/wC8v867avwM8HC/xoeqPHIMZHGCeDmuiihRIgYyMY/OuetFB4wSxPpXSWy7bf5yMY4zXiW1Pt5y0RDKqoMuNp9M9awbyQOxyvA5xWxqLoAsjHgHHr+lYN1IMAnOPX1pJGtJXVz0T4KyH7PrERzgTIw/Ff8A61Y/x7hT7Zo8w/1hSRfwBB/rWh8FJAbjWFHT92f51D8eYGki0Z1XgPIu73wOK9P/AJhz5xe7mn9djh9HuVt4AhIAPQepq5cPc3Ue0EhT2A6Vi6SjrIkgYhunIyK15XufnCb2HbGFFcDPpeWzKKwbFbLEkc8GqEUrWeopMsn3ZA3uOavN5+CSgVsYOaga2LKPMO7GT0xiknZl1FzRaZ9M2ky3FrDMh3LIgYH1BGalrn/AVx9o8I6a24sViCEn1HFdBXtwfNFM/O6sOSco9mFeS/GbTHiubbUoMKsw8pzj+IdD+X8q9arE8X6Omt6FcWrDMgG+M+jDp/hWdeHPBo6MBiPq9eM+nU8CtMuoQHPbI71NJp3lJl2wT2zVZYntb0qzbSDg1tadDHIWJUs/QZ614ex905WXMtjGZCWGFIUHqa9Q+EWq7o59NkYnH72PP6j+VchcWieYei/UdfXNSeFb6HT/ABFDNHlFRiCezg8EflWlCfs6iZwY+msTQlFI91oqtpsgksIHX7pUEfSivdTurnxMlZ2LNFFFMQUUUUAFFFFABRRRQAUUUUAFcz8QJvL0RU7ySgdcdMmumrjviS3+g2i+shP6VjiHalI6sFHmrxXmecogaTuTnAFaBhdovlb8+ao23Nweu73PFaJYx/KDznqOleLE+vlfZGfd3JjULICO24DiqTXUJGAAwx61e1J0eIoxyM9KwZ442HyZH0o3Oimly6nQ+ALH7f4xs2BzHADM3px0/WvcK81+DmniOG/vGBJJESE+nU/0r0qvXwseWnfufI5vV58Q120CuO+KUjJ4ejQEAPOoJ+gNdjXE/FYZ0O39pv8A2U1df+GznwKviIX7nlNjMEnwXxjjnpW+LyHZuCtKehx0FcytsonDSBiSew5roLNkhjYG3lbP9/AFeSrH2c4rcq31xKz48ohR05rIu58khoymBWzdXcLRspVAxOODmsa5wI3Y/Nj1qVubQdlsegfBJN0mrTA/L8ie2eTXS/FPS/7S8I3JVcy2xE6Y68df0JrI+CXlnQb90HzNc/MfX5RivRJUWWN45AGRgVIPcGvWpQvS5T47GVnDGuoujR8yaPMvm/MC2McetdUGg2Myhj/wHgH0rB1rTzoXiS9sipARzsJHVT0/StG3ZthHVWOcE15Ulyux9bzRqRU47MZdSxEOHAXAwMGs1pl+XjAJxgd6uTW6bSzHPNVHhGGUMOh7c1NzXSx7B8J7gTeFtmeYpmUg9fWu0rzT4MzBYtTts8hlkA/MV6XXs4eXNTTPh8xhyYma8wooorY4jxb4o6H/AGfrJuoE229z84wOA/cf1/GsHS7h4oi0ZBcnaM17d4r0dNb0Wa1IHmgb4z6MK8JngltJPInjaJ4ydykc5rx8XS5J36M+yyjFLEUPZS3j+RLdytsJMjsc8nNVYZ1VwyKD7E/rWnbWqurMy5AB61hMpSZ/KHy54rlemp7KUZJxPobwlfLqPh+0mH3gmxh6EcUVzHwkuvM066t+fkYOM+4x/SivcoT56aZ+fY2l7GvKHmd/RRRWxyhRRRQAUUUUAFFFFABRRRQAVxHxLdfKskPqzY/Ku3rzb4lXAk1SKIHiKPn6k5rlxkrUmd+Wx5sRHyOXsRvy2OnpU9zMsa/MGBIqnZo5jLLlcnFJMS8T7uQOma8lbH1vJ7xDM4kU7xnP6VQVcyLwTzgYq1dfKgHr6VseDtPXUdTto3AZRIC30HJpwTk0kVWqqlTc3seo+EdPGmeH7SDbhyvmP/vHmtmgccDpRXvRjypJHwlSbqSc31CuV+JEXmeHt2M7JVP8xXVVR1y1F5pF3ARndGcD3AyP1qKseaDReHn7OrGXZnhkCYnTODg963v3bxDzVBBHQisdlxuHRwfWr1sXMXPbsTXiJ6n2sveSZlanZQqcxJjPUmsqeILGUbq36VvXiliCGG0cVk3YIBG3kn0ovqbwk+WzPRvgmuzS9TQdBOp/8dr0mvNPgq/+i6rHz/rEbp7H/CvS69nD/wANHxeZq2Kn/XQ8i+M+neXqljqKjCyp5Tn1YdP0P6VyFhJ5UaEncO/evX/ihZC88H3bbQXgKzLx6Hn9Ca8d0pkZF3gnnpXBi4WqX7n0GU1vaYblf2dCS5bdIdpwvXiqe4luSc/zrQ1OS3jZsMAO3OfwrNjmhAyVJ/CuRqx68JXid18KLjyvEMkXIE0JB+oNev14N8P7wJ4ssioYbpNpH1GK95r1MG/3dj5HOoWxF+6Ciiius8gK8x+KPh5iz6pbAlWAWVR/CfWvTqjnhjuIXimQPG4wynuKzrUlVjys6sHipYWqqkT55srlwpR/lAHSq7RFpNyHcSc12vi7wo2kSNND81nIcA91Poa5+zsHlOLdGYeuOn414dSnKD5ZH29LGUqkPawejO5+EkDiK+mYEISqD+dFdL4IsXsNAiSVFWR2LkAevSivaw0eSkkfFY+r7XESmjfooorc4wooooAKKKKACiiigAooooAK8f8AGl0JPEF4du4K+3I9gBXrd1OltA8srBVUE5JrxXVX8y6d3zudize5Jrgx0lZRPYyaF6jkNsLmN1242E+vAqadQybVK8elU2HlEAKWyKay4yysyDjNcHQ+k5dbjbuPMY2rsPcmut+Flru1G4mPSFMD6muPe6JKxsS4PHHevUfh1ZmDSpZ2GDM/H0ArfCxvUR5+aVXDDuL6nW0UUV658mFFFFAHjPie1+zaxdwrnAckY9M8VVi+SDdk/nXS+PYQNalYYBZVbI+mK5ONt67Q+GUH8q8KquWo0faYSp7ShF+QkzbiM4IPf/GqNyhxxg8YPFSTTNjlflyelVXmZM7g208ZqDvUdDufg22y+1SLPGxGH5n/ABr1OvHvhBN5fiW6hPWSAn64Ir2GvYwrvTR8dm0bYl/Io65B9q0a+g27vMhdQPXg18zQNL9oaPnaPX2r6mYBlIPQjFfM9/GbTXLuJjjZKykemCawxq2Z6GQT1nD0LcVtuVjGgyBnOKr/AGd5GIJxjk8V0umzQNAqiQ9MnjJFY+pzxw+bFbgy55L45+lcDR78JOTcbEOkXCWGrW1xFIUMcisGPTivoq3lWe3jmjIKuoYEHPWvmGISiYnGVJxzXvfw9umn0CCNjkRKAM9R7V24OVpOPc8TPsPaMaiOoooor0T5kKKKKAIL21hvbaS3uUDxOMEGsnT/AA1aWbk7nlTOVR8cf41u0VnKlCbTkjSNWcE4xejEAwAAMAUUtFWZhRRRTAKKKKACiiigAooooAKKKKAOP8eTsiJGJQoIBCEfeyTn+VcGtkHgLNMpdW5A55zXbfEd1AtVVcTNnLei+lecWLvDO4QkEtjpkYryMT/FZ9RldNuhzLQ34NOea3JUgY9R1pk9mv2VkcYJ7qa17QoYdkkR3bRhg2Mknp+Vczql5OkxVGGwZIxz3xUuKSR10+epJoyRCY5IwQSARgmvcvDCGPQLJWADeXk15Dp8Au3giD7pd4+XqSCa9vgjEUMca9EUKPwrowUdWzzM7qaRgx9FFFeifPhRRRQBwHxIjAuYHHBaPkj2NcRatHGhaYgZ6V3fxNDH7KE4JVuce9efwwsQqudyn17V4+IS9qz6zLHfDoLqa2zyxK+1UpWh8sMGJB/QVpXFgrAcqpPGf6Vnz2YRtiMCO4FYHqRatoze+GUiN4zhKHduhcEjtxXtFeL/AA5Q2Hi23aRMecrJ06ZHFe0V6uDfuHymb/x0/IK8K+JVgln4wuGVeJgJQPr1/Wvda8u+MdqVuNOvQOqtET79R/OjFxvTv2FlFTkxKXc5fT/3MDyDuNoHAqreKFBOPmYd6QXQCRKOowasyos1nlh85GR24ry1tY+vgre8+pixKCTg89a9g+FrRto8yjPmI+Dn0IyP6140D5Uxztznt6V6n8I7jcb+L2Vv51vhXaojhzynfDt9j0eiiivXPigooooAKKKKACiiilYAooopgFFFFABRRRQAUUUUAFFFFAHEfElisVtj3rzezci7PzDk8n2716T8R42aK3ZfRhXm1oPLmYE/Mc9a8nEfxGfXZRb6sdTBdBoTtX7vzHPfiubvnVpWEPCgBAD/AD/nVnzD5GBJg96obGZwFIweSD3NZSd0d9GCi2zpfAkZOsbyv3Vzk9vSvWkO5FPqM1xfgPR2TT2u5AFklO0D1A712UQKxqD2GK9HCwcY69T5XNa0atZ26aD6KKK6jzAooooA434kpmzs37h2X8wP8K86RCZfL8zgf5zXqni+OO7tY4t4UxvvJPbivOLeKF7qWOUbNrHYf7w968nEr942j6fKp2oWfQRrcLHkgyZ4z2NMfTyG82XjjhB1raEcIRdx/DtWH4ku32qsWVQDDEdaz5dD0YSlUfLEvaOwe6ieJjlGDDDc8V2sV7c79wlfPpnI+leSaTK631uobq65/OvdotJt0jwN2f72a2oU5SvynlZrGNCaUtbmVJfXQcPFJJk9ic5/Co/H+nPqnhGRtn+kQhZ1A9R1H5E10VtZxW+dgJJ6k81PIiyRujjKsCpHsa7VSfK1J7njfWFGcZwWzPm8HDHaB8uVBH0rptPtnlgy33tpIycg1latYtpur3dtLGV2uwA6Ajsau/aVitgEbkLx7V5KXK2mfcSlzwi4dTJ1ayMUxZggyx6Gut+Fkpi10R5wJIyCPpXITO0jhsl67P4X2bPrIlKnESE5/Sro61EY5lphZKXY9Zooor2j4MKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDn/G0Ak0ZpCM+WwP9K8r2BZCSpzXtl/bLeWc1u/3ZFK/SvK9Q0a6t7x4nHQ5we/0PevOxcPeUj3soxMYRdOTMghWXLYHYCrekafJfajDHGOXbbnHQetaem6Bc3tyqpFgZ5Zuij1rvtI0ODTH3REscYyRUUqDm79DrxeYwpRcYu7NK1gS2to4YhhEUKKloor1D5du7uwooooEFI5Ow7euOKWigDC1XTTLYzSFiHX5wPXHrXlck5aaVpSA+7d7Zr2y6TzLaVP7yFf0rxe9t2t5XRvvDg152KgoNWPosmqc/MmX7Y+cu4k7ucAHjOKwfEgMb/Nu2+vFa1lMtq4Vzujzlh7YrN8UXUV1Ewj65zxWGlj26Saq6LQxbKTM6MnCq4NfR1u2+3ifruUH9K+b9PicyoMHBx7V9HWI22UA9I1H6V14Tdnj8QpXh8yaiiiu0+aOI+I+iC5thqUQG+Fdsg9V7GvNZLSQ5Cnj1zXvtxDHcQSQzKGjkUqwPcGuGj8GSpdyKAn2fPynf27cetefiqLcuaKvc9/LczVKn7Oo9tjz62sJJZo1gUl2IUDHU17D4S0RdGsMSYNzJy5Hb0FN0Pw1babKLhv3lx2J6L9K360w1Dk96W5hmWZPE/u4fD+YUUUV2HjhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNZFf76q31GadRQAiqFGFAA9qWiigAooooAKKKKACiiigArzT4g2LW995qLiOX5sj9a9LrE8X2v2nRZWWMO8Xz47474/CscRDngzty/Eewrp9HoeMSTeUrYBdW71Vnw0e0ZL5rclsVI3KmCT0qGHTGLD92SQa8pJn2sa9NK9yrolo9zqNvCiHLkAEfWvfo1CRqo6KAK5Xwh4ZXTiLy5X/SCPlX+5n+tdZXp4em4K76nyWbYuOJqJQ2QUUUV0HlBRRRQAUd6KKTAKKKKYBRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The epidermis is desquamating on the wrist and volar hand in a female with menstrual TSS; 7 days previously, the skin was diffusely erythematous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Toxic Shock Syndrome. In: Color Atlas and Synopsis of Clinical Dermatology: Common and Serious Diseases, 3rd edition, Fitzpatrick, TB, Johnson, RA, Wolff, K, et al (Eds), McGraw-Hill, New York 1997. Copyright &copy; 1997 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2768=[""].join("\n");
var outline_f2_45_2768=null;
var title_f2_45_2769="Hemochromatosis MRI";
var content_f2_45_2769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemochromatosis on magnetic resonance imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    72-year-old female with hemochromatosis suggested by MRI. T1-weighted images show a black hypointense liver characteristic of iron overload (small arrows) and a similar low intensity of the spleen (large arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martina Morrin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2769=[""].join("\n");
var outline_f2_45_2769=null;
var title_f2_45_2770="Nebulizers new designs";
var content_f2_45_2770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56942&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Novel nebulizer designs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 568px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI4AYkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6poorw/8AaC+MGr/DXWdJs9K0+wu0vLdpXa535UhsYG1hQB7hRXxz/wANWeKf+gFon5S//F0n/DVnin/oBaJ+Uv8A8XQOx9j0V8c/8NWeKf8AoB6J+Uv/AMXQf2q/FIOP7C0T8pf/AIugLH2NRXxz/wANV+Kc/wDID0T8pf8A4uj/AIar8U/9APRPyl/+LoFY+xqK+Of+GrPFP/QC0T8pf/i6P+Gq/FP/AEAtE/KX/wCLosOx9jUV8dD9qrxSemh6J+Uv/wAXR/w1V4p5/wCJHon5S/8AxdAWPsWivjn/AIar8U/9APRPyl/+Lpf+GqvFP/QD0T8pf/i6AsfYtFfHX/DVfin/AKAWiflL/wDF0n/DVfin/oB6J+Uv/wAXQFj7Gor45/4ar8U/9ALRPyl/+LpP+GrPFP8A0AtE/KX/AOLoCx9j0V8c/wDDVfin/oB6J+Uv/wAXR/w1Z4p/6AWiflL/APF0BY+xqK+OR+1X4oxzoeiflL/8XR/w1Z4p/wCgFon5S/8AxdAWPsaivjj/AIas8U/9ALRPyl/+LpT+1X4p/wCgFon5S/8AxdArH2NRXxx/w1Z4p/6AWiflL/8AF0f8NWeKf+gFon5S/wDxdA7H2PRXxx/w1Z4p/wCgFon5S/8AxdH/AA1Z4p/6AWiflL/8XQKx9j0V8c/8NWeKf+gFon5S/wDxdJ/w1Z4p/wCgFon5S/8AxdAWPseivjj/AIas8U/9ALRPyl/+Lo/4as8U/wDQC0T8pf8A4ugdj7Hor45/4as8U/8AQC0T8pf/AIuk/wCGrPFP/QC0T8pf/i6LCsfY9FfHP/DVnin/AKAWiflL/wDF0H9qvxTn/kB6J+Uv/wAXQB9jUVT0W7e/0ewvJFVXuLeOVlXoCygkD86uUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfIf7bf/I0eGv+vKT/ANDr68r5D/bb/wCRp8Nf9eUn/odA0fNoNKduBjOe9NpcUxhjiijtSgZOKBiUUvSkoEFKDSdKfEjyyLHEjO7cBVGSfwoAQU5QCeTiu/8ADXwl8S6wiTXEUenW7dGuDyR7KOa9H0v4C6YoDX+p31w3cRRhV/PNAXPnkLmjGK+o4PgX4XPDQ35Pr5+KLr9nrQLmM/ZLvUrVvwkH6mlcd/I+WsClIHavbPE/7Puu2AaTRLyHUUAz5Tjy5Py6frXkOsaTf6NePa6raTWlwpwUlXH5etAJoz/1o47Zp3Q8GkNACUlLRQAlFLxg+tJQIOwOaM9qMcUUAFHaiimAdqM9qKMUAFJml7UmKAFzRmkxSgdaAFopKDQAUhp1JigD9OfCf/IraN/15Q/+gCtWsrwn/wAito3/AF5Q/wDoArVpEhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXyF+25/wAjT4a/685P/Q6+va+Qv23P+Rp8Nf8AXlJ/6HQgPm2ikpRz7Uxi9qM46UlFACk8g0meaKVVLMFUZJOAKBmj4e0W817U47HT498jnk9lHqa+pPhn8M7Dw5aJM0ccl2Rl7qVckf7oPSqvwR8DxaPo8dzcxj7ROoklYjn2FejanfJGuCdsa8ADvUylbQ6KWHc3Zk7TQW422sQdu8snJNULi7YtmWcj2BxWHeasW4Q7VrMe9Ge7H3rPVnoQpU6fQ6yK7g3czHP+8a2dOulJHlXLA/72a8+jvT2jFXre/CnlSp9qGmaNwatY9SS5Z49tzGk6euMEVzPjXwbpXinTZIb23S6jI4LD95H7qetZ1hrUkYAV9w9Gro9O1NJyGQ7ZO6+tCk0ctXCxkrxPi34ofD+88FaidrNcaZIf3U+OR/st71wu4k195/Ebw1aeItBuIZYlZJlwcj7rdjXwzr2lzaNrF1p9yCJIHK/UdjWt7nnyg46lLdS5qOlpkXJBS0wGlzSHcWlpM5wMUZ5oAWlpuaUGgdwxSjHem5ozTFccADSEc4pCaM8UBcKUdaTI70+KOSZwkUbu56BVJNArjaK6DT/BfiXUcfY9Dv5Qeh8ogV1GnfBXxrebd1hFbIepmlC4/CgHJI83NJmu8+Inwx1PwPp1peX13b3CTsUIi/gPoa8/oFe5+nvhP/kVtG/68of/AEAVq1leE/8AkVdG/wCvKH/0AVq0gCiiigAooooAKKKKACiiigAooooAKKKKACvkL9tz/kafDX/XlJ/6HX17XyF+25/yNPhr/ryk/wDQ6APm0GkJHYUdaKYBTiBtznn0pMcUZ9qYwBGa3fBFol/4u0u3cZR5hkGsAAswCgknoB3rqfh0r2/jrRjOjx/vx94EUFU1zSSPs6ErZaP8uAAMVw+r6i0kpAPsBXX6jubR7hF+8gyBXmZkMkrEmsnuerT05vUseaWbBOTTvMt1A866hiY/dV2xmqjyLDE7sGdQOQnU/SqVk2l67KJn02WIwcfvx1renTTV2cleu07I1ZdTtrAotzFPIznA8oZA/GtW0je4XeoxH2LEAmqFveBFby3RV7JVXV7HT54Y7+6u5LZYjknzCB+QrXki9DmVeSN9W2HGcEVes9QaKVecMOhrnbe7tpoSbO5W5hIBWQdamlcqisp6c1zVIcrPRw9VyPVLC7F7pUoP92vkD9oS0S2+IEzoADNGrnFfUnhuR00Tc/3pegr5e/aJlEnxClUHIjiVamOmhjiF7smu55fRRRVnAKOtKKbmnRo8hwisx9FGaAFzRV+00PVrxgttp13IfaJq6XTPhf4u1Bh5ekyRqf4pCBQFzi80q5bhVLH2FehXHwyvdJvVh1qaMNjcY4jk/ia3bDSLKwXbb26A/wB4jJr3MDkVfFRVRvlizysVm9LDtwWrR5XZ6Xf3sqxWtpNI7dAFrs9I+EXivUwrfZoLZD/FPMFxXXD5PujH04pGnkUYEjj/AIEa9GXDC6VPw/4JwrPW/sfiFh8BZ2x/aXiLT4D3WMhz/Ous0j4F+FIiDfatcXpHURMErip3beDubJ966TwBO0WvRje2GUggmuWvw86UJTVS9lfY3p5s5tJxtfzPQ9N+GXgSw2lNFjnYfxTturprKx0bTgBp+k2cGOhWIVTilyKm3kivneU9FzZfm1GXGEwgH90Yqk15Iz/M5NQSMcVWJO6rUSLnHfH2x+2fDWWfG5oZhJXylX2h8Q7YXnw21OMjJVS2K+LyME1Mjoou6P098J/8iro3/XlD/wCgCtWsrwn/AMiro3/XlD/6AK1ag2CiiigAooooAKKKKACiiigAooooAKKKKACvkL9tz/kafDX/AF5Sf+h19e18hftuf8jT4a/68pP/AEOgD5tTAPPTvXqHwy+DmteNrX+0HkXTtJzgTyjmT/dH9a880a1F7q1nbHkSzKn5mv0c0DTbbS9EsLO1gURwQqqrjgcVXS5E5NaI+fYP2f8Aw5bRBZpNSun7vwAfyqRfgR4ZZgBBqA+rV9BXt+bf/WOkY/3apQ63bNMqtcx5JxjbSu2Z8z7nJeA/hD4X8K2zTRafFcXUh3CW6XeU9gDWzqngrS9UkV5rKykeM7kZYgrKfUEV0t/OrEJE678ZwTUenCQ5Z8KR71DbZpCTTTRwEb/vJYHH72I7GU9xXDeJdEktJpbi2UtbPzx/Ca7/AMbWhtNXNxA20n5sjsfQ1UtL23u18q6xDKw6kfK9TGSfuvc+jq0ZcqxVFXjLfy7nkkcp+aMsQc5B9KaNR1aG+b91afYCMcn5jXo+t+CILomS3zC553RnKmuVu/BOrIcIYpl7c4NdUJK2p5FVKTvEwF1PSZLw20dy/wBqAyU2HGfTNS3GrPcMti+kbrXH+vZgf0q+fCOsEk/Yow/TcMZ/Ortn4N1ZgBKY4U92zWnMjD2ZmWsqW0ISNVTJ6KMYFdJomnS6gyvMNluOST/FWrpPg22tmWS5JmkHOXOFFad5qVpYjy4Nssw4AUfKtc1SSerO7CwnJ+zpK8mWbq4WztlOMNjbEn9a+efHfw58UeKfGF3eWVmPszEBZZJAAfevc7GCa/uGlnYs3Vm7AegrfjjIUAdB2rKLcndHRmEI4SkqDd5PV/oj5osv2fvEE2Dc39jb+xJb+VdRo/7PdpbOsusasblB1igXbn8a91WM1L5Z8scd6uzPEczzPTPhD4TtCD/Z3mkd5HJrrdK8I6JYcWulWcfv5QJroVgJ7VYggO8U+UhzMKSJLc7Yo0QDsqgVci0y+l2nCqCM5Zu1OvbYlzx3psM9wihckgcDNXFaGcpGF4w+G15rEDX1jLE94g+aMH7w+teOanp13ptw0F/byQSqejrivpCxvLuGUOjEVrXkWm65b+VrFhFKT/EVr6LLs+qYaKpVVzRX3r/M8fF5XCs3Upu0vwf+R8mHHNRuoIOBzX0Jq/wp8P3LFrOSa2J7A5Fc3c/CJFBMWogDtuFe/DPcFUWsreqZ5MsuxMH8N/Ro8VuV5XtWx4NdRr1tz3xXf3fwqZQAb6NjTNM+HT6fqMVx9oUiM5471NbHYScJWqLVP8jSnSrJxTg9GdTADVoDinLCV7U7bXwlj6W5XdeKhCfNzVwqewNRtGxPCmmIjulFzoepWp53wtj8q+IdQjMV9cIeqyMP1r7hWCYcqpw3yn8a+M/G1o1l4t1W3YY2XDcfjUSOigfpB4T/AORV0b/ryh/9AFatZXhP/kVtG/68of8A0AVq1kdAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8h/tt/8jT4a/wCvKT/0OvryvkP9to/8VT4b5/5cpP8A0OhAeK/C+3ju/iFoEEpwjXaZz9a/RSNQl4R/Ai4Ar81PDt8dN1/Tr1T80E6P+Rr9ItOulvLWxu4yGS4hVs/UVT2M6m9z5k+NXxj8W+HfHF7pFmtnFaQ4MeYgSQfU158Pjx4wDA7rEkc/6gV0/wC17pJtPGVjqAX5bmLaTjuK8BYn8qlFpJq59Q+HPjtouvWUK+JjNpmqINpmhXdG/vjtXU/8Lm8F6HaGd9WuNSmUZSGJOp9zXxiaBTFyo+idE+OureJ/HMVnqVrbLo97N5YjVPnRT0+b1r17VtEuLCQNEhns+obGcD3r4w8JzfZ/E+lyg/duE/nX6CWcxNvG3VWUHH4VE6akrnq5fmVTBvlWsX0PPbK8lgMn2e4ePaeEPIqy2sXjRhpFiYeo4Ndjd6Jpt9ktH5Uh6lOKyZ/BYK7be8IX/bFY+/HY9v22XYn3qkbP0/VGCdWmHHlD25pj6xdE7VWND781pN4WkaRVXULYnOAM80+PwfcGY+bMBjj5RRz1GaLDZXDWX6nOXF7PcF1nlZgOynAqzoug3mrhAqmKEHJdhiu1svDenacqyyr5kvq3P6V0emhHbO0Ki84o9m3rJmFfOaOHhyYSFvP/AIBzsmnR2MaWkC8KMsT1JqSKzJ7VvLbied5X/iPFWRDGnpXTFWR8lWrSqycpO7ZgpYnuKtRafuGCO+a0ndAOKIJgZCPamYXGJpSipU09FYH3p7X4xxVeS9J6GlZiujP1G2jS4kB9c1nYiUnpVvW5HaRXHRlrAcSse9XFESkayTQqe1aQSVIhIsW5SM8HNc1HbysehrYg86KJMOR+NNpEpsfJeSE48oqfcVXkaST7wq+t05G2VVf6jmh2TGUH4U07CZlSwu5ztqI2UjHnitNnY8BaQxzsMhTj6U7sVjMGnD+I80/7HEo5NT3DwwAm5uoIh/tyBf5muf1Txh4X0wH7brtmpHUK4Y/pSuUot9DXaKFR0qJvLHRa4DUvjT4IsyQl5PdMP+eSf41yuqftD6RFkabos8x7GZ9v8qXMilSk+h7OrnaQq9CDXx58cbY23xK1VSuN5D/mK7S+/aH1qTP2LS7O3+uWryjxf4jvvFWuTarqhT7TKADsGAAKTaN6dOUXqfpB4T/5FbRv+vKH/wBAFatZXhP/AJFbRv8Aryh/9AFatZmwVneINc03w7pcmo63eRWVjGVV5pT8oLHAH4kgVo1wHxy8N6p4s+Hl1pOhRrJfyXFvIoZ1UAJKrE5bjgAmgDqvDviHSPElk93oWoW99bpIYneFs7HHVWHUHkcH1rVrxHxh8LNRj0VodNVfEFxqer/2jq0t0sCSt+7ZFMKOphXGf4lY85HbFTwB8Mdbjn8HReLraSSz0vTruGdRfE7ZTdmSAHYw3AR49hgDHFAHt2l6jb6pa/abTzvK3tH+9geFsqSD8rgHGR1xg9RkVbrjPhJomp+H/CJsdbXbd/bbqbHmB/keZ2TkE/wkcdq7OgAooooAKKKKACiiigAr5C/bb/5Gnw1/15Sf+h19e18h/tt/8jT4a/685P8A0OgEfNvTkda+/fgfrA1j4VaFcbt0kKeU/wBRXwCK+uf2P9Y+1eDNX0ljlrSbzV+jVS2ZE1oTfth6V9o8I6dqKqM28+0n0Br5BbrxX3p8f7FNU+Eerb8bo4xIp9wa+C+tShwegwjmjHNPbBPHSm0y7FjTn8rULaTONsqn9a/QLQJvP0ewkHIeBG/Svz2B2kH0Oa+9/h5MLjwXosmck2yfyp9AW5023I6U19yjhiPxqRelEi5FSd9B2ZlzRor7gi7hznFSG+mIwCBT7pMRk1URaEjuqNSWpOJHkYF2JrZsji2bHfisVRjFadncpHEVkOPShnk11qaaZAAHSkcE964Lxz8U9A8FiIaq07SSglEiTOce9eX6r+0/ZIWXTNClkPZpZMD8sU0zhcGfQ7qabGpWVWGTivkjVv2lPFNwSLCzsbVT32EmuI1j4u+NtWLC41y4RG/gi+UCncXsmfc92RHI2ThfrWTe6/pVgpN7qVpAP9uUCvgqTxRrsqusmr3pDnLZmPNZ013cXDZuJ5ZP95yaLj9j5n2/rHxW8FWUZE+twyMvaIb/AOVcXqnx98J2qt9it7y7bthQoP518ncZzS5ouUqMT6G1L9o+TBGnaHGvoZXz/Kufl/aF8VtMrJFZpH/zz2k5rxmjtSuV7OK6Hvdl+0fqq4F5o9rJ7qxFW7j9pO78vFroUAf1dya+ec0ZHbNO4ezj2PY9S/aE8X3QYWotLQH+4mSPzrjtU+JnjDUyftOu3YB7RttH6VxvejvSuUoRXQv3Wr6jd5+1X91Ln+/KTVBiT94k/U5pDRQVYPwopD0ozigQtIaDQaAP068J/wDIraN/15Q/+gCtWsrwn/yK2jf9eUP/AKAK1aQgooooAKKKKACiiigAooooAKKKKACiiigAr5D/AG2/+Rp8Nf8AXlJ/6HX15XyF+25/yNPhr/ryk/8AQ6EB82969g/Zs8c6d4M8T339tzmDT7q3Kl8Z+YdK8foqgaufU3jX43+HfEHwz17T4Vkiv5CYreFud654bNfLNHekpAlbRC0dqSigaDsa+5fg3P8AaPhzob+kO38q+Gu1faH7PM5n+GGl5PMZZf1o6BfU9STpTmHFInShjxQdVF6le4AMB9aooozWjIAYGqiOtM7JS0HBajuPukVMOlRSqSOelSzkmrnzR+1IcXukD/Yb+deC17x+1PkanpHPHltx+NeD0LY5ZbhS0lFMkUU7tTadj5c5oAM0Ck70oxnmgYoNFJRmkMXrSim9qM0wHEdcUlGTmjmgAz2pOtFB65oBhRRjAooEFBopM0Afp34T/wCRW0b/AK8of/QBWrWV4T/5FbRv+vKH/wBAFatIQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8h/tt/8jT4a/68pP8A0OvryvkL9tz/AJGrw1/15Sf+h0AfNvaikopjFNJRRigApfpSUtAC19dfswXAm+HhjzkxXBFfIoxzmvqj9kycSeFdTgH3o7jP4YoFLue9RjpRJHk8EU9B0pJly9CN6E7JsiaM+Uy9zVVbdu/FWyD6mmhSTTOj2yfQYIQgyeahuBkYHStB0OAKrSxn0qGc1WbvY+V/2rFZda0fj5fKbn8a8Hr6D/a1IGqaMgxlY2z+dfPhprYxvcKBRQKYDuKKTFFAC0UduaO1AwooxQKAFooooAKKKXHpQNB2ptKaDQDEoopRQISincUcUAfpz4T/AORW0b/ryh/9AFatZXhP/kVtG/68of8A0AVq0hBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXyH+23/yNPhr/AK8pP/Q6+vK+Q/22ufFXhrJx/oUn/odA0fNdLSikpjCkpRS0CEpaCOlFA0FfRP7KF4Yf7Xjz0ZWxXzvXtf7Mlz5etapHnhowf1poiroj69t9s8YeI59RU7Rhk5HOa5WxvmhIKsRW7Z65HIP3q59xT5X0MY1rKxO0Q9aaIwDnrU41Gxbk7hTW1OyT7qkmizNPbId8zcIvFU76RbeM8gyfyptzq+5SIwFFYl3clycmly9zOVXmeh83/tTsX1TSmJ5KN/OvBiK92/afO6/0k99prwrFI1hsNpaWjFBQlLRRQMO9FAoFABRS0lINhRjvQfSkp1MBBTl2+uDTaSgd7EpGRwRUeMHmkp2eKAbuJRR3o70CEop2OtIcUDsfp14T/wCRW0b/AK8of/QBWrWV4T/5FbRv+vKH/wBAFatIkKKKKACiiigAooooAKKKKACiiigAooooAK+Q/wBtv/kafDX/AF5Sf+h19eV8h/tt/wDI0+Gv+vKT/wBDoGj5sAoBwaXmkPv1pjCg8UdKXqPagBcggALz60lFFACivUP2fLtbfxfNCzAGaEgD1Iry6tHw7q02iazaahbk74XDEeo7imiZK6sfa0N0NoyalW72HhuK5LQtcttc0iHUtPkDwyD5gDyjdwRVtrrjrW8dTz5ppnSm/Pc0q3wPeuWN4w4DVJHdE45q7IzudR9qz3qOWfPesaO496q+INdtNA0ibUtRlWOFB8oJ5kbsAO9Zz0NYK54p+0hfpP4gsbRTloY9ze2a8drX8U61P4h1261K6+/M2Qv91ewrJrA9CKsrCcUUYooACeKKQ0tAxKKU0hoEAoo+tFABRRRQAUUdqBQAlKKOtGKACil6UYoGIDilzntRTTQI/Tzwn/yK2jf9eUP/AKAK1ayvCf8AyKujf9eUP/oArVpCCiiigAooooAKKKKACiiigAooooAKKKKACvkL9tv/AJGnw1/15Sf+h19e18qftj6Dq+r+JfDz6VpV/fRx2kiu1tbvKFO/oSoOKAPlsHg0Vv8A/CF+Kf8AoWtb/wDACX/4mj/hC/FP/Qta3/4AS/8AxNMowO9FdB/whXin/oWtb/8AACX/AOJo/wCEL8U/9C1rf/gBL/8AE0Ac/S1vf8IX4p/6FrW//ACX/wCJo/4QvxT/ANC1rf8A4AS//E0CMEDINJXQf8IX4p/6FrW//ACX/wCJoPgrxT/0LWt/+AEv/wATQMd4P8W6l4WvfOsJN0Lf6yB+UcfSvZ9C+JXh3WYQLqZtLu+6S5aM/RuteLf8IX4p/wCha1v/AMAJf/iaP+EL8U/9C1rf/gBL/wDE01JrYzlTjPc+joLu0nUG31CylU9Csyj+Zp731lagtdajZQqOpaYH+Rr5wHg3xWOnhzXR9LGX/wCJpD4N8Vnr4c10/Wxl/wDia09qzH6tHue3a98VPD2ixEWDNqt32CfLGD7nqa8S8Y+LtU8WX/2jU5v3an93AnCRj2FN/wCEL8U/9C1rf/gBL/8AE0f8IX4p/wCha1v/AMAJf/iazbb3NoQjHYwM+lJk9K3/APhC/FP/AELWt/8AgBL/APE0f8IX4p/6FrW//ACX/wCJpFmBR3roP+EK8Ug/8i1rf/gBL/8AE0n/AAhfinH/ACLWt/8AgBL/APE0AYFJXQf8IX4p/wCha1v/AMAJf/iaD4L8U548Na3/AOAEv/xNAHP0HrW//wAIX4p/6FrW/wDwAl/+Jo/4QvxT/wBC1rf/AIAS/wDxNAHPmlrfPgrxT/0LWt/+AEv/AMTR/wAIX4p/6FrW/wDwAl/+JoAwMUVv/wDCFeKf+ha1v/wAl/8AiaP+EK8U/wDQta3/AOAEv/xNAHP0vSt//hCvFP8A0LWt/wDgBL/8TR/whXin/oWtb/8AACX/AOJoA5+lzit8eCvFP/Qta3/4AS//ABNH/CFeKf8AoWtb/wDACX/4mgDApK6H/hC/FP8A0LWt/wDgBL/8TSf8IV4p/wCha1v/AMAJf/iaAMCkroP+EL8U/wDQta3/AOAEv/xNH/CF+Kf+ha1v/wAAJf8A4mgR+jnhP/kVdG/68of/AEAVq1meF0aLwzpKSKyOtpCrKwwQQgyCK06QBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXgP7SvxT8R/D3WNGtvDz2qxXUDySedCHOQ2Bivfq+Rv22/+Rj8Nf9ekn/odCA5T/hpfx/8A89tN/wDAUf40v/DS3xA/566b/wCAo/xrxMUtUM9r/wCGlvH/APz103/wFH+NJ/w0t8QP+e2m/wDgKP8AGvFeKQ9aAPbP+Gl/H/8Az203/wABR/jR/wANLfED/nrpv/gKP8a8T70tIdj2sftLeP8A/ntpv/gKP8aX/hpbx/8A89dN/wDAUf414mMUtAWPa/8AhpXx/wD89dN/8BR/jQf2lvH/APz203/wFH+NeKUUBY9r/wCGlvH/APz103/wFH+NL/w0r4//AOeum/8AgKP8a8TFL3oHY9r/AOGlfH//AD203/wFH+NH/DSnj/8A57ab/wCAo/xrxaigLHtX/DSnj/8A566b/wCAo/xoH7Snj7/nrpv/AICj/GvFadjvQFj2j/hpTx9/z103/wABR/jS/wDDSnj7/ntpv/gKP8a8VAo70BY9q/4aT8ff89tN/wDAUf40f8NKePv+eum/+Ao/xrxcUmOaAse0/wDDSfj/AP57ab/4Cj/Gj/hpPx9/z103/wABR/jXi1LxQOyPaP8AhpPx9/z103/wFH+NH/DSfj/P+t03/wABR/jXi5xQaAse0f8ADSnj7/ntpv8A4Cj/ABo/4aT8ff8APbTf/AUf414vgUuKLCsez/8ADSfj/wD566b/AOAo/wAaUftJ+Pz/AMttN/8AAUf414uBS45pjsj2Y/tJ+Px/y103/wABR/jQP2k/Hx/5bab/AOAo/wAa8YxzSUaBZHtH/DSfj7/ntpv/AICj/Gk/4aU8f5/12m/+Ao/xrxcjijApBY9q/wCGk/H3/PXTf/AUf40L+0n4+LAebp3X/n1H+NeLDGKdGAWX60Csj9ONEuZLzRrC5mx5s1vHI+BgZKgn+dXazPC//ItaT/16Q/8AoArTpEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXyN+23/yMfhr/AK9JP/Q6+ua+Rv22/wDkY/DX/XpJ/wCh0IEfNQFFHaiqKCilpKLgJThSUd6AFxRQOKMUAKOtLQBQTSGJS4x+NAooAcozmjFIOtKDQMXFKBir+h6Xc6xfpa2i5Y8s3ZR6mvdvC/w302xto3u4BJNjJL8sf8KaJbseB29jc3OBb208v+4hNNuLSe2bbcQSxN6SIV/nX1xp+j2lmALW3VMd1GKvNocN/hJIfNY/wsgb+YoFzHxnijFfcCfCXQmsTc6la2YOP9WYBz+Veba/8IdDlv3ax09oIyfuicgfl2pD5j5o20u05HpX0ra/CDTggxY2px/fkcmnaj8F9IubL/VfZp1zh7Vjz9Q1MOdHzScc5pYo3lcJGjO7dFUZJr3S0+ClkZkNxfXWwHlMKN349q9i8HfDbQdJtAdPt4YJMfMxXdKf+BH+lAOR8yeGvhfrWrLFLdr9hgcgKJBmRvov+Nes6Z8CtGtI0Gtm8Zn5VllC5/CvYrDSo7a6EEEYB3ZZjyfzrT1m1NzaPt5KfdpE3Z4bqf7Puj3EbNpWpXsT9ldVkH+NeceIfgt4j0xZZLJrfUETqsbbZMf7pr6WhuXh24JDfWi5vGuSiSYY5xkjpTC7Pj238CeI5mI/sq4iwcZmGypLvwB4gtgC1nvz2Vua+uZrcR3YDjeQeC3NSXEKHiSNW9iKB8zPiDUNPu9Pm8u9tpbd/SRSM1V4FfaXiXwVpviDTGjkhViw+6w/kexr5R8eeGJ/C2tyWj5aBiTE57j0PuKY07nOAU5AAy/WmrT1++PrSKP0w8L/APItaT/16Q/+gCtOszwv/wAi1pP/AF6Q/wDoArTqTMKKKKACiiigAooooAKKKKACiiigAooooAK+Rv22/wDkY/DX/XpJ/wCh19c18jftt/8AIx+Gv+vST/0OmgR800uKSlplC0Yo7UUAJQaWigA60Y/Ol/lR2pAHbFJ1NLiigYtAopRzSASig8UgpiZ9D/s8eCZbyxbUXhJD/Mpxx7V9CWngyMx7ppcEckVz/wACGgtPhvpoUhXlQMT7V6RaSwSyHLk4GfrSJMN/DMFqUKnenvV+2t7WyG5EUP64q1Iby4t3eFF5OUB9Kw7gXkRJuY2x7CjcRY1RmlQtvz6AdBXOyxFTmRs59abe6pJLIY4cqi8E9zVURmTDOxLdt5poCybuKIhTjPtU9vcQscujFSOeKoNC4GWkRfotRxRPI7K7swxximIkuEEsjbFUJngZ5FaOmPdQEK8ZkiPQ9xWf/Ze+PfDKQe4JqKA30Mu1CxGePegDpprtrY7ypGeCSOtT22q278SoU9xyKz2trxBieNgzAHBGaZ9muVUkRsB/sijQCvrtlEJ1ntZFZHPKjtWI+0MNpyQa6JAPtBXaCu3BDCkXR7XUVb7Ofs04/h/hNFxkETiW3S4RQzpwwNVpnMjFiMHrSrBdaNdYuEPlng+hFaL2iyjzISDG3NAFG1nIgdR1HSvFv2gfD0s2jtqbKuYiHz39D+le0xgQ3BUDNcf8WIm1LwzdwkDaUYH24/8ArUIEfHgPNSRn5h9aiIweRzT4j86/WkaH6Z+F/wDkWtJ/69If/QBWnWZ4X/5FrSf+vSL/ANAFadIgKKKKACiiigAooooAKKKKACiiigAooooAK+Rv22/+Rj8Nf9ekn/odfXNfI37bf/Ix+Gv+vST/ANDpoD5qxS0gNBpjHCjFIPenKKYwA4p/lsEDFSFPAOOK6r4e+CNU8ba7Bp2mQttc5knZTsjUdST/AEr7f8O/C7w7p3hTTdFvNPtb9LQZEk0Q3M56saQXsfnsF4zjikIxX6D+I/hX4bvfCmr6XpukWNrNeRnbIkYBWQD5TntzXwPr2lXWiavdabqEZjuraQxyKfUUr6gmZ4NKB1pMj0oBFMYUYpacsUjglI3YDkkAnFIBuPShR6dalgglnYrBFJI3oikmu58E/DPxB4g1SFPsT2tuGBeScbRj2HenYls+jvhWWi8DabEwwyoP5V6domUt2uZCcdFFYPhXw0mlaVb2U0hYIuCQK6C+hlihht7MZRh+VDIG3fiQ26rHCoBWsTV/El5dwlFUIvcgU2XS5ln/AH0Z3euSau2+lfMqzS/fyFGMAGlohnKwiRiTya2NJ028vZQEVVjH3nYcAVurobwugARm6+xpNZ1NIYvstsQOMOy9vYUXCxh31u3mEQESR8jPQ1pabo8MGni7v5GR35VAcYHvWZYkmdT2B71sXaPq17FaI5VR3HpQBivdxRXMixAsmeCa2dBjW5uUEkZVc7smrltoEdsxXyx5nZ25qxdFNLi3StumP3VouBY1+/EM0USkZ6mmWSSXk4xlYh941j2FvNqt75spIX1rsEENjagEhVA60hmZrGlwzHdCAsqjBx3rnY7S5t5jtB4rR1PVCZNlueWOM02e4aCIeYeevPWgQv2h5Y/KvbbzEPeoBaR2Y821cm2Y4MbdVqP7RdXDLHAGZ2/hUdPqa19P0Q70lvJ9zDnYOgNPYNzl9TjW3u0lU/u5Bwa5zWrSXUdPuo414IyWPTFek6/oyyWcjQEYA3Y9MVyc5A08xRjl1OcUAfDPiOyOna9f2jY/dTMv61nx/fH1rqfidbNb+NNRDDG9g49wa5VBh14702aI/TXwv/yLOkf9ecP/AKAK06zPC/8AyLOkf9ecP/oArTqSAooooAKKKKACiiigAooooAKKKKACiiigAr5F/bc/5GPw1/16Sf8AodfXVfIv7bn/ACMfhr/r0k/9DoQHzTThTaUVQx1OQ8gUwfWnwgFwCQMnr6UwufeP7Mdp5Xwm0qSS3iidy7BlXlxngk16yeK5L4U6ZHo3w90KxhnFwiWqESDo2Rn+taHjfVDo3hm9vkfY8a5VvelbmlZEm7Xyr+2bb6NBNorwwLHrUxd5HVcb4+nzHuc19A/DnxWvi3Qhd+RJDNG3lyBhgE+oNeLftT+Gv7a1/RbiUusMcDJle5zmqjSlKfItw5klc+R+n1q1Z6deXjAW9tI+e+3ivWtK8HafAhcW6sw7vya37bT40GFUDHQAYr0aWX31myXUtseWaX4Ev7pgbl0gU9hya9Y8A+F4NLsri1UtKHcOSwGemMfSr0MCImAo3etdF4YjHnyL3Kg11PCUoRdkZe0bZv8AgDw1pkEuqiGwgSeeDO8IMkg10mh6f5LlyWMnb2qLwzIttq0Iz/rAYz+IrUs3CahGhPysTGfYjoa82tG10jSLLtsbhHbdh0HPvV03MVwF2NjHHFVrcsZHV3KAHbu9DS/Z8TFCu185BHQ1xll+S4jggVdwLdi1EFt9pKyOVIBzwelYvntHOY50JjPUHtWuL8rYS+QisFQkFR1pNBcqeJ9YWGIW9scTHjcOwrmbO2lvZQkYz6mo4IbnUbgyvn5+S3pXWaebXTrbBI396ewblKTRprVVESiTIyfXNT2Hn2dx5wgwSME02819Q2Ihk1Ql1SVhukkGPShJhc6XUr1C1rLuC45YZrBuZP7X1bAJAYhVHtVEXi3fyswz2xU9jvtpxMmCw6E9KdhXOvX7NpVoAxUbenqa5nUr6S7cZfIz07CqMrT3d5h5hLIx4UdBTdQEcMRijcyyZwzDoKVh3JJruKF1MeGZe9VJJri5kyoYse5qsJNo+6M0fbWUHZ1piNzTbt7OIxyMwRvvletb5jtbm3Bt53R8cc81xlgJ7y6ijOQpOTWlKJrO7kEDn2J7GkMuao09tZyRtcZBGDzXOaUxaHaedpwKjvJrq4z5zEnvRoPyTXCHtgimB8t/HuLyfGpAXAMXH515sh+dfrXs37R9ps1u1uAvO50J/UV40g+dfrQzSOx+mnhf/kWdI/69If8A0AVp1meF/wDkWdJ/69If/QBWnUkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXyN+23/yMfhr/r0k/wDQ6+ua+Rf23P8AkY/DX/XpJ/6HQB80GlFdPovgXxJreiSatpWlXF1Yo/lmSMZy3oB3rqNA+B3jrWNrLpBtIj/HdME/SqA8xHNdl8NfAWo+OdTmt7ErHBbKJLiU9UU+g716la/sx62oie+1iyTJG9EUkgd8Gvo74e+BtF8I6U9ppFmsTvEBJKeXlPqTTuhXOb+Btje+F7NtFv72e7gbBgMpz5eP4R6CvUdX0+01e1NpfwrNASCUY8HFcrd232dhJF8rocgjtVOTW7iCYh7hstzmuiVFyfNASfc7mKO00q0SG2ijhiUfLGgwK8t+M11FNp9n5xUuZDtHoMVp6n4utoI/MvrpPlGAB1P4V414z8UPr2p+YAUgjG2NT6etaYajLm5mROXQLNo3jmCjHHFV/wCPHvWbaX6wShnPy9DSWWsWtzrENmksZlkbAXdk160HZEPVG3FJtnCsMrW5px+z3sbIThxwO9bNl4VtW8qS5eRiwHC8CsL4sxT+GtFttV0rj7DKHdGb76emaidW0WSo6m82onTyt5cHZHCfMbccYUdTV/wl4w0jxbqF8+i3BmFuyuxCkAZr5P8AFPxB13xHbm1up1itM/6qIY3D0Y9TXo37LWqG21rV7EgETwq4z6qa8adZzZuo2PqK3Je5nDcqW/pT7q5e1xgGRB0PcU/SUjmimAyHU5LfWrEVhC0p6s57g9a5ijl9W1SWUYjj2t03GtXwo8i22y4UgHOCe4NdB/Y0ci/OifQ0LpcULssbEDHencLHJ3YewlltIjtydyn2rGuJ5txDE5rrfEunylIrhBukh+9t7rWA9v5oMzjC9qAM1HbrjJp2yWRgAOT2q2AvCoKmt2W3PmPy3amIgFp5KeZO+09gvWrAQFE3+YQx4yacqCaYzXB+UZIX1q4oNxKrNhYkHQUgHzSRWEMkq7ASuFXHJNYBU+X5hYruPHvUuqziW6G3kJxUThmSPkkZpgNZSwwoq7Y2SKQ83J64p+1IokB+8eTT57iNIyqfM2OfakBd0Qq93NISEjQYB96S+O+/fEgIGD9TUmlQwxaT5l0Squck+1Zc8sNxM8sAZYl+UDPOPWgYy6LRXEi7eW5qnaAw6ijMCBJ8prUghaTYxy2TjJqr4juY4SkcS/MjAk0wPIf2mNNB0hblV5V0fPp/Ca+a1wJF+tfZHxp04az8O7qVB+8SMsPw5r44H31x60MuGx+mXhf/AJFnSP8Ar0h/9AFadZnhf/kWdI/684f/AEAVp1JIVm+I9d0zw1o9xquuXkdnYQAGSV8nGTgAAZJJJwAASa0q4v4teE7zxf4WitNKuIINSs7yG/tTcg+S8kTZCyY52nJ6e1AFjRPHuj635I06PUneS4W2ZJbGWFomZSys4dQQpA+9yK6Vry1SB5muYRCi72kLjaq88k+nB/KvN9Q0Lxl4k1Lwve69a6JZf2Vq6XjQ2lzJKfKETqxLMgyxZhgAcDvXL6V8G7vTfht4bsIbLRpdcsL6K91KCVmEGprG0u2ORwpJwJBtypAIxjFAHuEV5ayxiSK5heMp5gZZAQU/vZ9Pesmy8V6Td6trenrciOXRzCLt5cJGvmxh0wx4PykV5Rrnw68Vyy3lzommeGdPTU/Dt1olxYRXEiRWhknmlDxkR/MSJeeFG7J6Uxvhf4ph0nX4bY6TI9+dHHlTMGEiWtskcygvG6oxZflba2OuAaAPZJdatFutNhj8y4S/8zy54F3xKEXcSzjgDjA9TVua+tIbdp5rqCOBQC0jyAKM9MnpzXhPhz4SeItOXSFl/s6KKzv9YuPKjuGdY47q28uJVOxc4Y88LxzjtUt98GbuPwP4QtNLt9MXUtMKy6nbFgkd9J5Xlli7RSAsvO0sh6npxQB7ujrIivGwZGAKspyCPUU6uX+GWgS+F/A2maPcRrFJbCQeWtybgIGkZlXzCibsBgPugDGBwM11FABRRRQAV8iftu/8jJ4a/wCvST/0OvruvkX9t0Z8R+Gv+vST/wBDoQGt+yN4wgk0K+8LzFVu4XN1Bn+NT94D3Fe9vqgXIY81+d/hHXr3wx4gs9W05ytxbSBhz94dwfYivojxt8ctNj0+wutDh+03N1FvliLbRA3cGnK+6FY99n1uBB87AfjWrY6nDNPBtdSki7QQeK+DPEPxT8TazvQXItIj/DCMH86xdI8ZeIdMlga21a8CRSCURmUlSQc0Jdwsfeev3cdtJKjsB1ryrxH4qtbcu4lUMOu44rxjxv8AGnXPEjo1rBHp+F2uUO4sfX2rzO+1G9v5GkvLmWVicnc1dkMQoITi2eweKPHunSSfNMrOO0XOa4XUPHUrZFnbhR/ec5rjSKaRSli5vRaB7NGjfa7qN6T51y4U/wAK8Ct/4Ty7fHmnFz95iuTz2rjsHNbXhFr9PEWntpMTTXvmqI41GSxz0rOFV86lJg1pY+87DTZZLGCcIVjOPmbqa5f4z6cjeAdTaYxiLyiMkYwe1epaLbSnw/bR3a7JfLUuo/hOBkVk+NfC1n4p8M3ej3jyxwXChS8f3lPY1o8VJslQPzm24r0j4DXLQeO4lQFpJI22gHuOa+gfDvwX8O+FrG9hu4xql9OjJ5868IpHG0dj718v+GruTw18Q7WWJihtb3Yf93dj+Vchd+h91eF7pTNIjkK79j3rqUVUuAFAyea5650tb23hv9OYJM6BwB0birWj6i07iO5BS5j4YHvSA6FuOlULmRYElmmb5UGTV0MGbjpiue8WXsNtatGGDSyHG0dhQMz7vX/PilSKIKjAqM9cVh/aAluYXB2/w57UwXaJHgqKptOZn3Pyq9BVWJLEYYncBgD1qN2Z3wRlh0H9aesb3CAsSkeegqzDbJaTZkBfjigBGSVbaNiuVYUPf4jCKm0dKkub0yALtACrhQOwqMIkoUYzSApRsNzMR1qzEpkhZiQNvIFSPZASnbnAGeangs2WJ8ntzQBTuGLS++KlELGAt8oz3NVmkUk45ZRjjvViKx1C+RFWJkjJ4ZuBTAdrN15vlWsD/uY1AOOhNVrCKTJ2DPqKlfTLlbgxptcjrirAiksVYTAKSuR70DLK3RjtSipz1B9Kx9Qg8yB5HHzMc5q5ZSCSfnkYqvdbml8tjhBQIqXIF94XvbVxuBTBHt0r4r13T30vXbuylXa0MxXHtnj9K+zbUyxSOoPyvlSpr5b+L0bJ4xMki7WkRc/UHFPoXFn314X/AORa0n/r0h/9AFadZnhf/kWtJ/69If8A0AVp1AgooooAKKKKACiiigAooooAKKKKACiiigAr5G/bb/5GPw1/16Sf+h19c18jftt/8jH4a/69JP8A0OgaPmsdafmmc04ZxVDFoFJzRQMXNGaKSkMQ55pCaU000yWS2yq9xEr/AHGcA/TNfaHwr+GPhvTdQsNa0yzkS5SMYkeQsMkdcetfFakhgR2Oa/Qf4XXAfwZpc5IwbdG/QU+hEmeghdkW3PAFRxMrLjGTVBNRa4BXAQFcg55NZ940lpZOXnIJztIpJCuaV7bxz28vmLhgMg1+fvxSszo/xJ1qIdEujIv0ODX23b6062/zy5KyCIlu5Pavif4x6zFrvxF1e8ghESCXysBs528Z/GhoFqfZvw51YX/hDS5FkLJLArI3cHFdHHJbXF0JZHEVynG49GFeFfsz+Jo9T8JnSJXAubA4Ud9p6GvVNRWRoWZOSOuKVhljWPEcn2yS3hJECHAZe5rNk26iu/d+8HrWXOCrrkjJ61PYwu7FkZlwO1MRBeJJEwR1I96ltLcum5hhBV9d1xDtuI96HuOtNlhk8v8AcNvjHYcEfhQBFNLtRY4+1aEJEpUOc7lxn0NZccaluWwa0IjAifPNj2xSAqzxtDK4I5x3qWwZY1cyZD9BWhsjv4AisDMp+VvUVQRAsvlyDkHBoGO/eRgyNlmPQZpB9ou2EKNjI59z6VJfQlEjEMhO44x3FS2lxFpcTlf3l2eF9qALAtoNMt9uN8+PmJ9a1TNI9hasT8w6gVjEeRZ+bfOGkdtwTPNXJdTRbVY4xzSsBMzKjyzDAAGTWDPK1zKZpDxnAHtU2oXTELAp6jLkVWX7hUdqaAntUQnKjHNRatGE8uTrk8U60lCMDkYNTaywlgXaB8nPFAHPxH/TCc854r5x+PyhPFNuAuDhz/49X0NLuEyOv4183/HS8S78YRiM52Jz+Jqug47n3X4X/wCRZ0j/AK84f/QBWnWZ4X/5FnSP+vSH/wBAFadQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8jftt/8jH4a/69JP8A0Ovrmvkb9tv/AJGPw1/16Sf+h00NHzUKdmminL70xi5o60HgnBzRQMM0c0UUgEPSmmnn1pD68CgTGV9XfDT4laCfAWl6QLxhqsEKxyRFSO/Y96+VMVueC5PL8RWuCMsSP0qkS0fePh8y3Ph2S4trgPJH9xjg8VQ1ST7VbndJI9ygyyoCQR9K5f4QeJ7CDwtqtnKxN2CWSPPLZHQVqeH/ABFBYanDfXoYW8kYz/s54rels9DGe6OM8Za5NdeFdVgtC8UseJQ4G0g9OPSvk24LNKzOSWJOSepNfVHxD1y0uNR16S3QLBcoFRwMAY718tXPM0mOm4/zrCRrBG54A8WXfg7xFDqVpllHySx54de4r7T8D+I7LxXoseoWDbo5Bhl7qe4NfBB9a9S+BPxE/wCEL11rbUWY6PeHbJ38puzj+tIbR9O6rbtHenAyo647VdtJgqhQuBVO4v0uZEu7SVJoJFDK6HIYVNbsk/8AqWCSf3T0NBJZ3ERBYuqknB71AbrDcjDetIwnSbEgK/yqU26yHLDmkBF5kFwcTDY/ZxUM1lInzKwkj7EVPLCEQjZxVEyT2r74HO3uh70wLdlcm2lBOdvcVtTot2iyJjzCMhv73/165tbyC54J8qU9VPQ1p6dM8J8uQExE9R2PqKLAPDFww6MvrVeNPn8xT8y881cv4j5gkBwx6kdG96z5X2qdzHPr60DGzeZJKZJmLHtVk3CqkYZd3riqL3YY4QU9JA2A2elAi7dmOe5ieIFImHU9zU88CLjHOV/WkjjRraEjkxGq97MzEkZzQMsW4htkVnG5/SnTyZt7h5F5xnisXMinJY1Bc6iseRczKid8nFAjP1WdbfRL25kfy/LjZs+lfIGv6k+q63Ndkkq74XP90dK9n+MvjaCPT59I06ffJP8AKxU9F75rwZOXX609i4o/TXwv/wAizpH/AF5w/wDoArTrM8L/APIs6R/16Q/+gCtOoEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfI37bZ/4qPw1/16Sf+h19c18jftt/8jH4b/69JP8A0OhAj5qpQaQUoNUULQOtIKXpQMWjNJn2oB5pAO7Uh60uRSUAI3HWpbO4a1uop0+9GwYVHxTD1piZ7t4VtW1ZLa7iWRLOaQIZIzyCete0LpaW+20mntxawQfM2zzHVRz9M14d8ENShbwfrdldztDHa3EVyGAz8pODx6V9B+INdtbG3tZLVPMiaJOVUAPuXqa0UrGTR5b400m3k8Ea3f2TvJcQw/aFz8pCbtpyvavmdjX0fF47/wCEj8K65bzwCJ2tri0CgAs23lSTXzc3FZvc0itApdvehTTgaRSR03hnxxr3h6MRafeN9nHIik+ZR9PSumPxp8Wh1aKW0Tb6Qg15mDS55ouHKj2LTv2gfFEI23trp92nvHtP6V3Og/HjRrpB/aVpJZTd+NyfmK+ZNwNKGouHKj6ov/jToYB8m7gx/sxOxrlNW+MlpJnyLi5b2jgCfqa8C3UbqYcqPUdQ+Ks8khNtBcOexmmx+gqWz+MurQq2+Bs/w7JiAPrXlOaXd7UXDlR7rpf7QN6rxwappKS2n8TJIfMX3Ga6LUvixpIiEsU1vtZdy5Ys3/fI6GvmjNG7mgXKj1vXPjBdykrp0TH/AG3+UfgB/WsW2+K3iGJiX+zSj0ZDx+Oa8+JozRcfKj27w18dLqzmVdS0/fC3DGKUnH4GumufjfpAik8p33HlR9mPH6182ZzSZoDlR7Fq/wAZ7qVStpFMxPdyEH5CuB1vxrreqs3nXbRqf4Y+K5omgnNFxqKQO7SMWdizHkknJNNX76/Wihfvr9aQz9NPC/8AyLOkf9ecP/oArTrM8L/8i1pH/XnD/wCgCtOkZBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXyN+23/wAjH4a/69JP/Q6+ua+Rv22/+Rj8Nf8AXpJ/6HQgPmoUoFIBS1SKCg0tIaAFFKoBB5xim0tIYo4o70UUAHakP1pcUEUAdt8MJj5muWq5/e2DMPqpBr6DW4h1nwbohjnjWdYI1dC3zDB4496+Z/AWpWuleI4pdRd0s5I3hldRkqGGM471teL/ABCLWa1tPD+qPLBFB5Uk0QKCTnK8H0pk2ub3hKwuD4k1rSwMSLdldn+8CK8uvoWtr24gfho5GQj3BxWjoXiLVNDvpbzTrpkupVKtIw3E5789/esqRjJI8khLO5LFj3J70iktRlKPakpaBi+9GaSl4zQAA0opKWgAzxR7Zo4ooGA60403HvQTQAufeikxxmlxxTAWjIpBRQAuaKSlxgc0gEpcdqTqaO9MA7c0KPnH1pGPNCffHPekM/TTwv8A8i1pP/XpD/6AK06zPC//ACLOkf8AXnD/AOgCtOkYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXzV+1h4G8S+Ldd0Gbw7pFxfxQWzpI0QBCktkA19K14P+0z8SvEfgCXRF8Nz28Qug5l82ESZx069KAPmsfBj4hf9Ctf/AJD/ABoHwZ+IX/QrX/5D/Guj/wCGkfiJ/wA/2n/+AS0f8NIfET/n90//AMAkp3Ksznf+FM/EL/oVr/8AIf40f8KZ+IX/AEK1/wDkP8a6L/hpD4i/8/th/wCAS0o/aQ+In/P9p/8A4BJRcLM5v/hTPxC/6Fa//If40v8Awpn4hf8AQrX/AOQ/xro/+GkPiJ/z/af/AOASUf8ADR/xE/5/tP8A/AJKAsznP+FM/EL/AKFe/wDyH+NL/wAKZ+IX/Qr3/wCQ/wAa6I/tIfET/n+0/wD8Ako/4aQ+In/P9p//AIBJQFmc6Pgz8Qf+hXv/AMh/jS/8Ka+IP/Qr3/5D/Gug/wCGkPiJ/wA/2n/+AS0f8NIfEX/n+0//AMAkoHqc/wD8Ka+IOP8AkV7/APIf40v/AApv4g/9Cvf/AJD/ABroD+0f8RB/y/aef+3JKT/hpD4if8/2n/8AgElINTA/4U18QP8AoV7/APIf40n/AApr4g/9Cvf4+g/xrof+GkPiJj/j+0//AMAlpP8AhpD4if8AP9p//gElAanP/wDCmviD/wBCvf8A5D/Gj/hTPxB/6Fe//If410P/AA0h8RP+f7T/APwCWk/4aQ+In/P7p/8A4BJQGpz/APwpn4g/9CvqH5D/ABo/4Uz8Qf8AoV7/APIf410P/DSHxF/5/tP/APAJKP8Aho/4if8AP9p//gElAanP/wDCmfiD/wBCvf8A5D/GgfBr4g/9Cvf/AJD/ABroP+Gj/iL/AM/2n/8AgEtH/DSHxE/5/tP/APAJKLhqc/8A8Ka+IP8A0K9/+Q/xpf8AhTXxA/6Fi/8AyH+Nb/8Aw0h8RP8An+0//wAAkpv/AA0j8RP+f3T/APwCSi4amEfg18QeP+KXv/yH+NB+DXxBzx4Yv/yH+Nbo/aR+In/P9p//AIBJR/w0j8RP+f7T/wDwCSncLswv+FNfEH/oV7/8h/jQPg18QP8AoV7/APIf41u/8NI/EX/n90//AMAkpf8AhpH4if8AP9p//gElFwuzCHwb+IH/AEK9/wDkP8aT/hTXxB/6Fe//ACH+Nbv/AA0j8Rf+f6w/8Ako/wCGkfiL/wA/2n/+ASUBdmH/AMKa+IH/AEK9/wDkP8aP+FN/ED/oWL/8h/jW3/w0l8Rf+f3T/wDwDSl/4aR+In/P9p//AIBJRcLswh8G/iB/0K9/+Q/xo/4U18QP+hXv/wAh/jW7/wANJfETvfWH/gElJ/w0l8RP+f7T/wDwDSgLswz8GviB/wBCvf8A5D/GlX4N/EEOP+KXv8Z9B/jW3/w0l8Rf+f7T/wDwDSpbb9o74hyXESNfWG1nAOLNOmaAuz7X8PwyW+g6bDMpSWO2jR1PUEKARV+qulTPc6XZzykGSWFHYgY5KgmrVIgKKKKACiiigAooooAKKKKACiiigAooooAK+VP22/8AX+Gv92SvquvlX9tr/X+Gf92Sga3Pl0ds0Cgnnij6UywopfTg0D3BoGFLjIPNIetLyKAExxSUv0pDmgQH3oo5pOaBi0lLzQM0CDtQKKSgBRS4PXtSA/nXVeC/AmveL5f+JTakWynD3Up2xL+Pc+wpBc5cVc0zTL3VbtbbTbWa6uG6RxIWNfRfhb4A6JAyN4h1C8u3/iWIeUn+J/MV6lP8MbLSfCcsXgi0igllOZCBh5V9NxJ/nTik3a5lWrOnByjG7XQ+QrfwLqshYXAgtnXgoz7jn8MiszVPDOq6dHJLLau9un3povmUfX0/Gvo/UPDD6fp1t5tvdrfM5EsbQt8o7c45rZ8P+C7yXWontIpTYMg86SaMqpB6rg9a6Z0qajoz5vD5vjZV+WcLp20S2v8A1qfHRNNJr6u8a/Azw1cXFxNZyyWE7HcI4T8oP0OR+WK8S8W/CrW9E8yWzxqNqoyTGMSAe69/wzXLofT81zz3PNLSEFSQwII4II6UZoFcfnJyaKaDS5NBVwBo70mTSg0AFFFHemAtIeTSmkNACYqey/4/IP8Arov8xUPJqay/4/IP+ui/zFAj9O9B/wCQHp3/AF7R/wDoIq9VHQf+QHp3/XtH/wCgir1IkKKKKACiiigAooooAKKKKACiiigAooooAK+Vf22v9f4Z/wB2SvqqvlX9tkgXHhnIyNslA1ufLo96Xk9aPypRmixoHbpzRR9acKYDQM96O2Kfj1pG9qBjMZHFJTugPAptAgxRSmgfhQIMUnbrTjSGgYhHSkpxHSjBFAju/g54Gbxx4pS3m3rp1uBLcsvUjPC596+19L0FNMtILfSoILaCBQqAYVUFeBfsesjN4ijK5kXypM/7OcV9Nahpoutjq+Fx6VLJe5Sg853aKTVY7hiOYlwf6Vt6bIVgZHQIsXAPqPWsOE2dgSLSISy95HratJGnhXzEWPd1A6GhEl8YYA8EHpVe+kSG3aRyAqjJpc+XgK+QOMVBdIkzA5VnA4WmByer2Rn1A3UAt+UHzTAFR+dUZNLupIyL6ytpID0mt414/Fa2p7mG5eS2vbLbFnG4Nlh74qO10w2Egksp2aFuVKtj86kD5s+O3wzh+wXGvaVGEuIBvmRFwJU7t9R+tfOY4PNfoR44to30DU2nUFBays4/4Ca/Ph8bzjpniqWwCUuabRTAdmlzTc0uaCri/jS0gooAXtRRQMkgcfjQMSp7L/j8g/66L/OoO/NT2X/H5B/10X+YoQj9O9B/5Aenf9e0f/oIq9VHQf8AkB6d/wBe0f8A6CKvUiQooooAKKKKACiiigAooooAKKKKACiiigAr5V/ba/4+PDP+7JX1VXyr+22f3/hn/dkoGtz5dpfSm07jHHWmWKKcOtN3YPQelLngUx3Ht3xnFJg/jXovwQ8CweOPEssGomUadaxeZKYzgsegGe1e3XH7P3hCT/VyajF9J8/zFJ6C5j5JOaQ5zzX1NP8As5+HW/1Wq6mn1KH+lZs/7N+nf8sdfvB/vwqaLoVz5spR0GK981L9nK7igZ9O1xJnH8EsG3P4g1zlp8A/GM7OZFsoIwflZpCd30AH86E0HMeTj3HFNb2zXrNx8B/F0QOz7HJ9HI/pWVL8HvFcTuklrH5g5Co4PHr2o0Hc869qWu8b4UeKlPzWJA+oP9agk+GPiVIJpmspFji6lkbLfQAHNArnYfsqakll8UYYppjHHcwPFt3YVj2BHevtxY2gOEG+I/w9x9K+A/hDpcsPxK0uGWRVcSYZRuVh+YFffVn5sMCLO3mKBxJ3x70iWNNpaTyb9ih+/Y/iKjmtbr7SrxSRmEDGwjBH0NX9qSAHCsOxpPL/ALrMPxpWEVlhm2NuA3HpzVS5tbxtrQCNZAc7nPFahV+0h/IU0o56u/4YFFgKE+npKS8oAPcjgVCUjjXbbqGx3/hH41feMdwCfViWrO1a9gswAW3yAZ2Lyf8A61AHnfxw1xPDvw81iYhZJ7iEwqGOMluM/hXwaetfTH7UOp3E2nxQzyD5yGEa9EXPHPc18zmqASiiloABS0lL1oGApeaQUtAwpe1FJQMKsWX/AB+Qf9dF/nVcVYsv+PyD/rov8xQB+nWg/wDID07/AK9o/wD0EVeqjoP/ACA9O/69o/8A0EVepEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXyp+25/r/AA1/uyV9V18qftuf6/w1/uyUAj5cpc0wU6ncsd9DTlpgNdR8NvDx8U+NdJ0gZ23E6hz6KOT+lNA3ZXPpr9nPw4NC8CpezJtu9SbzmyOQg4UV6rmtC38N/ZreKC3YLFEoRFA4AAwKf/Ykw6MPyqXqyEZlMK56VqnR7gdwaWPSZww3AYqbDF0u0EgywrYFlHtxgflS2Vv5CYPWrNUIpNp8R/hFZsOjxPNPIUGS2OnpW/TIl2qfck0AYz6JEf4B+VUb7RYo7eV9i4VSa6qqGuYXS7lsclcUAfHvjKSTSfiml9AhV4Zg46DIxX1d4X8RWepeHrS9SfzI3XDMASUPcH3FfJfxfVz4rv5QsgCEAMvPavRPgb4ql/4QrWC64ns2ygcYDlhxxSWxTR9FQPDKN0JUhuQUPWpjuHRvzFedfDPWX1uGeFrY280ADM8b/KxP+fSu5YXCD7+fqp/pTJLBM+ePLIH1prG55wIx+BNZk+oajDIUh09Jk7OJgufwIqu+o61J8qWMEJ9XuM4/IUAXbxZlQtJIxH91eB+lcX4t1a30uxuJGP3FyVA5/H0/GrPiXUbvSdKu9S1WcywW6FzDbJjP4k18p/Eb4oah4hZoLOP7DYZOEB+Y+59/rmgDF+MXiuPXdQWGCVpCvMpbPynstea06Vy8jMxJJOST3ptO4wopKWgBaKPrQT+VABS5pKWgYuaSlpO9ABViy/4/IP8Arov86r49asWX/H3B/wBdF/mKAP060H/kB6d/17R/+gir1UdB/wCQHp3/AF7R/wDoIq9SJCiiigAooooAKKKKACiiigAooooAKKKKACvlT9tz/X+Gf92SvquvlT9tz/X+Gv8AdkoGj5boApaPzoLFr2L9lWNH+Ldhvx8sUjL9cV4+BkZrqfhp4tk8E+MLDW4oTOLdjvh3Y3qeCM00KSuj9IqK+drX9qfw8+Bc6FqsX+6Y3/qK2rP9pbwPMB5w1O3P+3bZ/wDQSaRNme30V5Ra/H/4ez4zrLRf9dbeRf8A2WtSP4z+AJYy6+JrAAc4Zip/Iii4WZ6HRXCaX8T/AAnrDN/Z3iDTHCnB8y5WL9HINF58VfB1jfw2Vx4j0trmU4URTCRR/vMvyr+JFFxWO7psRygNcVZ/FLwdffaFtvEOmloDiQNME2/njP1Famn+JNMuIFaG8hdTyCkoII/OkOx0dZviE40mbHpTU1e1b7soP/AqpeIL+I6NdN5gAVCxJ9BQwPjj4pam3/CU6kUldCJtoKn0rpPhld3UGizrdXBeG/YqoJBwyjg8V5t4wvlvNcupY1YlpGYliCDz9K9D+HCi60i3tpWS3aJvPDnng9qcRu9j2n4FK6jVWb+EoK9fXnmvOPhTa/ZNHuCylXnbfz1x2r0WD7gzQSKy+1UriJQ5kx8xGM1oVR1SXaioDyeTQB558YZfL8A6wR1MW39a+ItZBWRycEdQRX2r8ZGH/CvtXLYwI8818WTs9wkqNnJBxntSYnpqcyetJSnrSUxhSikpRQAtGKKKBgKWk5paBi4pMUtJTGA/Wp7L/j8g/wCui/zqCrFl/wAfkH/XRf5igR+nWg/8gPTv+vaP/wBBFXqo6D/yA9O/69o//QRV6kSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfKn7bf8Ar/DP+7JX1XXyp+23/r/DP+7JQNHy7Rij8aKDQKcKaDS0wHZpQaZR0oAkDdaUNx1qMGjPHWgCXcCOQKNw6VF3pfxoAfuHcA/WrMOpXkO0RXUqhRgYY8VTNISaBM2YvEmrw/c1Ccf8DNXI/G2urE8Z1C4ZGGCpmfBH03VzOfeloEaT6q7kkwpljknJr2/4A2B8Xu1u7+Uljh5ATuMgzwB6Cvn4c16J8IPEWo+GNXOoaXIPMA2tERlZB/dYUIGfdOh2K2gCEAKBgYreGAOOlec+APiFaeK5fsjWklnfqm9k3hkb12ng/pXdGSRRiNCT6seKRBZmlSGMvIcAViTSNPK0hGB2FWXt5JnD3D7iOg7CmSoFXAFAHmPxpaWfwdNaxDmeVIseoJ5r5X8WaXHoclzGoLAfcYjnkV9O/Ha6MHh21ihkCTy3K7OcHjvXzd4/a5ewdr9lNxnG4DhhQkTJNnl5pKdnqKSmUGKWkpRQMKWgUDp1pDAUtJS0xhRS/jSfjQAYqey/4/IP+ui/zFQVPZf8fdv/ANdF/nQgP060H/kB6d/17R/+gir1UdB/5Aenf9e0f/oIq9SICqWt6na6Lo97qeoyeVZ2cLzzPjOEUEn6nA6Vdrjvir4WvvGnhddCsr2Oytbq6i+3SEZc26tuZU4I3EhevGM5oAt+G/HPh/X/AAkviW1v4rfSMurzXjCARFW2kPuOF59fUetaCeJtBe1t7ldb0xre4UvDKLuMpKoIBKnOCASBketeQXfwX1s2es2MHiGKa0m1iDXrQzoY2a5CsJllEQUKrEggpjBUcVo+F/hC9j4g0W+1W30aW0szeyS2oMtwDJP5ZDgzZycoxJ468DqaAPU7fXdIudWm0u21Swm1OAbpbSO4Rpox6sgO4de4rm/BHxI0fxlG1xpVrq8VgIXnF/d2Lw2zKjbWAlPykg54z/C3oa5jw18LdR0rxfpl7PfWDabpeoXuoQSxxMLy4a5DApKx4wu48jO7A4Fcz4N+B2r6X4L1nw5qFxo0H26wktv7SsnuGnZzKJFDoxCbMAg7QCQB6mgD1OT4ieHW1nRtO06+i1STVHuI4pbCaKaKNoYjKwkYP8pKjjrz1x1q5beNdBbSLPUNR1Oy0tLmITLFfXkCMFLbQSQ5UjPGQSM8Zri08A6/e+JvDurakvhuzGlfaUaPTIZE8xZLYwqSSOSCenQDpmuK/wCFZeJrXVNK0K1g02dI/B8ukz6hdxSPbIz3HOzAz5m05AOOM0Ae73XiPQ7TU7bTbvWdNg1G52+RayXSLLLu6bUJy2e2BT7LXtHv9TudOsdV0+51C2/19rDco8sXOPmQHK/iK8mi+EOrWPjDSb/SdWtrays1sEnmzI0t2ltEiASRNmMsdnDggrkcEjJn+GvwlvvCHiXT7q4ubK9tdP8AtCwXRmuPtDJLk4MZbywckZPOcdAeaAPZKKKKACvlT9tv/X+Gf92SvquvlT9tv/j48M/7slA1ufLtKQRTccdaPxpmgtL1pv0NKKAFoNH8qOfWgBTRSY96UjB+8DQAUZpMe9GPegB3ak5zSH1ox70AHelpMH1oH1oEOArt/hnp82p6j9ltiFkc43McADuTXD5PrXafD2eVI9QEG8SCPJdR91TxQtwex6ne66fC14IfDtzH5luw33qDmRu/J7e1e2+FPikl5p9i2p2jPJOVTzbbGNx4yVPSvl3UY3j03zHYtgjB9z3ru/hFq0c15Bps5+dZldM9xmhkW0PrRmAXOGxXOa3rS2tpeSpC3+joW3SnahOOma355lW3Jz2rxD44eK4tP8P/AGGF/wB/cOcgdgKQjzLxN48vNavmOtwwzwB/3axrtMP+6ev51w/xKhlW0SYtut5VDRv6j/GnWCC8l8xg5kHDA/dI7Gjx80kXhmMTyNJ8+xMLgL7VVwlo7HlppKcabSAUGlpBR+NA0OopKB160hju9A60lL+dMYtJR260fjQMKnsv+PyD/rov8xUH41NY/wDH5B/10X+dCEfp3oP/ACA9O/69o/8A0EVeqjoP/ID07/r2j/8AQRV6kQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfKn7bn+v8Nf7slfVdfKn7bn+v8Nf7slA0fLnFFA96KCwJ5zxS8E9vwo7daPypggpVpPyozQMWko5oHvQAtFFGfpQAUUmacSMcUDEpKDRn1oELxXYfCzUjp3i223IssFx+4mibo6N1FccDz2ra8H3EVr4ksJpyfKSVS23rjNIT2PdtV8LpqWnzrod0s9oHPyNw8Z9GFZPgzRLvSvF+kyXUEkVukw33BBCj6nsKonxHpljfTzw386y+YcpBCc9ehLYH861dO+Komla0e1dIOgmRsOPc44/MU3ZkK59Oy6jayWx231qy46iZT/Wvnj4r2Tan4wAgiN1bNEAXjOQjeuaiOs6JOjTrqt0DjJBt4jz9c/0p1t8QdPskFvtQ7gStzMhY57cDgD6ZoSAz/DPgjUHkCyjyoXPzysMBQOSea4X4z+ILTUJbPStGV10uwLBWYYaaT+Jz/SvQbXWb7VdUWea6je1jViPLkBjXg9cf1rxLxa26ZGOMMzHge9JkN+8kc4aSnUlBYCl4xSU4UAgxRx2opR65FAxBThzSUUDDAoNLnikzTGJViyH+lwenmL/MVBmrFkS13bjIwJF/mKEI/TnQf+QHp3/XtH/6CKvVR0H/AJAenf8AXtH/AOgir1IgKKKKACiiigAooooAKKKKACiiigAooooAK+VP23P9f4Z/3ZK+q6+U/wBtz/X+Gv8AdkoGj5czxxS03mnCgsKUAEGkpe1MaE70tIetKDQIAQDQaDQKBgKU+4ozigEgYoASg9KCKOaADPHNFJ3pRQAYq5pA/wCJhCcE4bNUjWt4Wt2u9btrdFLO7YVQcZpCNa8uoLdrp44/Om3Zy/3VP071i/2veO/MxVSeVjAUfpWjq9tLa3N9DPG8cityrDBFYagKwZgSvsaFuxnX2skJtnQ2+4soYSb+QO/FYsmq3EMrRxyFoQeEcBl/Wpbe7t0fekybSv3DEdwPpn+tZV1KZrgsBtUnIFFwSOl0m7juLxhHG8chjOQp+VuKxvEnWAdDgkg1c0Z/JvpDjP7o49uKxL8uTGJC5bBPzelK3UzlFc1ynikpxGDSUwsApaSlFA0H4UUd6WgYUUdqOtABSUoFJTAB9Knsv+PyD/rov8xVerFj/wAfkGf+ei/zFAj9O9B/5Aenf9e0f/oIq9VHQf8AkB6d/wBe0f8A6CKvUiQooooAKKKKACiiigAooooAKKKKACiiigAr5U/bcBM/hrH92SvquvlP9t3/AF/hn/dkoBHy2KWkpaZYtFBOewH0FIaBi0DrSd+1OAPpQAUUlHegGL9aKSlzQAA0Gk60tAxDR+PFFLQIBT4JZIJklhZklRgysvBBHeo/50ZxSGdR9uXX3bz7lYr+XhjcP8sh9mPT6Gq2peHNT05DJfWk0MZGVkKZR/ow4rAP0Famk+IdY0iMppup3dtE3WNJDsP1Xp+lICnjAAFaFhpd7qFxtsrWeYf7K5A+p6VLJ4t1pzl7qJm65NtET+e2q1/4j1jUIvJu9RuXh/55h9qf98jAoDmsdRa3tj4WmnmvI7XULx4tiW6vu8pvViOPw5rhrud7q4eaU5dzk44AqKimtCWH40EUUUAJ9KX60UUCACiij8qBhS0hHNA60ALR1opPpTAKnsv+PyD/AK6L/OoKsWX/AB9wf9dF/mKEB+nWg/8AID07/r2j/wDQRV6qOg/8gPTv+vaP/wBBFXqRAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV8p/tuf6/wz/uyV9WV4P+018NfEfxAl0VvDcFvKLUOJfNmEeM9OvWgEfFFFeyf8M2/EX/nx0/8A8DUpf+GbviL/AM+Nh/4GpQXdHjQODSmvZP8Ahm74i/8APjYf+BqUf8M3fEX/AJ8dP/8AA1KYXR41ShsV7J/wzd8Rf+fHT/8AwNSj/hm74i/8+Nh/4GpQFzxsciivZP8Ahm74ij/lx0//AMDUpf8Ahm74if8APjp//galAXR41xRXsv8Awzf8RMf8eNhn/r9Sk/4Zu+Iv/Plp/wD4GpQF0eOUley/8M3/ABF/58dP/wDA1KP+Gb/iL/z46f8A+BqUBdHjdNzXsv8Awzd8Rc/8eWn/APgalH/DN3xE/wCfLT//AANSgLo8a60V7L/wzd8Rf+fLT/8AwNSk/wCGbfiL/wA+On/+BqUgueNg0Z5r2X/hm34i4/48dP8A/A1KP+GbviL/AM+Wn/8AgYlAXPGqTNezH9m74i/8+On/APgalH/DNvxF/wCfHT//AAMSgLnjPeivZf8Ahm34i/8APjp//galH/DNvxF/58dP/wDAxKBXPGuKK9l/4Zt+Iv8Az5af/wCBiUf8M2/EX/ny0/8A8DUoC6PGqK9l/wCGbfiL/wA+Nh/4GpR/wzb8Rf8Any0//wADEoC54yaUV7L/AMM2/EX/AJ8dP/8AAxKP+GbfiL/z42H/AIGpQFzxqgda9l/4Zt+Iv/PjYf8AgalKP2bviL/z46f/AOBqUBc8Zor2Y/s3fEUn/jx0/wD8DUpP+GbfiL/z42H/AIGpTC54zVix/wCPyD/rov8AOvXv+GbfiL/z5WH/AIGpUtt+zh8Q47iJ2srDargnF4nTNAXPtjQf+QHp3/XtH/6CKvVV0qF7bS7OCUASRQojYOeQoBq1SJCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These devices are designed to release more aerosol during inspiration and less during expiration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2770=[""].join("\n");
var outline_f2_45_2770=null;
var title_f2_45_2771="Infundibulopelvic ligamnt sutur";
var content_f2_45_2771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ligation of infundibulopelvic ligament during vaginal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Suture ligament and placement of a suture tie on the infundibulopelvic ligament.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2771=[""].join("\n");
var outline_f2_45_2771=null;
var title_f2_45_2772="Hives (urticaria)";
var content_f2_45_2772=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Hives (urticaria) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/45/2772/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/45/2772/contributors\" id=\"au873\">",
"       Clifton O Bingham, III, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/45/2772/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/45/2772/contributors\" id=\"se1137\">",
"       Sarbjit Saini, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?2/45/2772/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/45/2772/contributors\" id=\"de128\">",
"       Anna M Feldweg, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?2/45/2772?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      HIVES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Urticaria is the medical term for hives. Hives are raised areas of the skin that itch intensely and are red with a pale center (",
"     <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"      picture 1",
"     </a>",
"     ). Hives are a very common condition: about 20 percent of people have hives at some time during their lives.",
"    </p>",
"    <p>",
"     Hives develop when there is a reaction that activates immune cells in the skin, called mast cells. When activated, these cells release natural chemicals. One important chemical is histamine, which causes itching, redness, and swelling of the skin in an area: a hive. In most cases, hives appear suddenly and disappear within several hours.",
"    </p>",
"    <p>",
"     Hives usually respond well to treatment, which includes medicines and avoiding whatever triggered the hives.",
"    </p>",
"    <p>",
"     More detailed information about hives is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"      \"New onset urticaria\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"      \"Chronic urticaria: Standard management and patient education\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HIVES SYMPTOMS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Skin appearance",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hives are raised areas that itch intensely and are sometimes red with a pale center (",
"     <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"      picture 1",
"     </a>",
"     ). In some cases, the raised areas enlarge and merge together (",
"     <a class=\"graphic graphic_picture graphicRef51694 \" href=\"UTD.htm?4/53/4944\">",
"      picture 2",
"     </a>",
"     ). Itching is usually the most bothersome symptom of hives, and it may be severe enough to interfere with work and sleep.",
"    </p>",
"    <p>",
"     Severe pain, blood-blister like spots, and bruising of the skin are",
"     <strong>",
"      NOT",
"     </strong>",
"     typical of hives. Having hives along with a fever and joint pains is also NOT typical. These symptoms suggest a different condition called urticarial vasculitis, which requires a different treatment. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"      \"Urticarial vasculitis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Angioedema",
"     </span>",
"     &nbsp;&mdash;&nbsp;In up to one-half of people with hives, a condition called angioedema also develops. Angioedema is similar to hives but occurs in the deeper layers of skin. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=see_link\">",
"      \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Symptoms of angioedema include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Puffiness of the face, eyelids, ears, mouth, hands, feet, and genitalia",
"      </li>",
"      <li>",
"       Swelling that usually affects one side of the body or affects one side more than the other",
"      </li>",
"      <li>",
"       A sensation of fullness or discomfort in the area of the swelling",
"      </li>",
"      <li>",
"       Slight redness of the skin, although the skin may also be normal in color",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Hives as part of a serious allergic reaction",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hives can also occur as part of a more serious allergic reaction. You should see a doctor or nurse as soon as possible if you develop hives or angioedema suddenly, along with other symptoms, such as:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Trouble breathing",
"      </li>",
"      <li>",
"       Tightness in the throat",
"      </li>",
"      <li>",
"       Nausea or vomiting",
"      </li>",
"      <li>",
"       Cramping abdominal pain",
"      </li>",
"      <li>",
"       Passing out",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      TYPES OF HIVES",
"     </span>",
"    </p>",
"    <p>",
"     Hives are classified based upon how long you have the hives. Hives can be:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Acute (brief)",
"      </li>",
"      <li>",
"       Chronic (long-standing)",
"      </li>",
"      <li>",
"       Physical (triggered by certain types of physical stimulation, such as heat, cold, or sun exposure)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Of course, when you first get hives, you cannot tell how long they will last, and so you cannot tell if you have acute or chronic hives.",
"    </p>",
"    <p>",
"     Although all types of hives look similar, they often have different triggers. Learning what triggers your hives can help you to avoid the trigger.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Acute hives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most cases of hives are acute and will not last beyond a few days to a week or two. Triggers of acute hives can include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Infections &mdash; Infections can cause hives in some people. In fact, viral infections cause more than 80 percent of all cases of acute hives in children. A variety of viruses can cause hives, even routine cold viruses. The hives seem to appear as the immune system begins to clear the infection, sometimes a week or more after the illness begins. The hives usually persist for a week or two and then disappear.",
"      </li>",
"      <li>",
"       Drugs &mdash; Many types of drugs can trigger hives, including antibiotics and nonsteroidal antiinflammatory drugs (NSAIDs), such as aspirin, ibuprofen, or naproxen. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=see_link\">",
"        \"Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)\"",
"       </a>",
"       .)",
"       <br/>",
"       <br/>",
"       Painkillers (eg, codeine and morphine), muscle relaxants used in anesthesia, and IV contrast dye used in X-ray procedures can also trigger hives. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"        \"Drug eruptions\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Insect stings &mdash; Stings from certain insects (bees, wasps, hornets, fire ants) can cause hives around the area of the sting. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?18/22/18786?source=see_link\">",
"        \"Patient information: Bee and insect stings (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?18/44/19138?source=see_link\">",
"        \"Patient information: Fire ants (Beyond the Basics)\"",
"       </a>",
"       .)",
"       <br/>",
"       <br/>",
"       If you get hives all over your body after an insect sting, this may be a sign of a more serious reaction called anaphylaxis. Anaphylaxis must be treated as soon as possible. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"        \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Food allergies &mdash; Food allergy can cause acute hives in some people. Food-associated hives typically appear within 30 minutes of eating the food. The foods most likely to cause hives in children include milk, eggs, peanuts, other nuts, soy, and wheat. The foods most likely to cause hives in adults include fish, shellfish, peanuts, and other nuts. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"        \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Physical contact &mdash; Hives can occur after you touch certain substances if you are allergic to them. For example, children who are allergic to dogs may get hives if a dog licks them. Other things that can cause hives (if you are allergic) include plants, raw fruits and vegetables, and latex (found in balloons, latex gloves, condoms, and other common items).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Chronic hives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chronic hives occur daily or almost daily and last longer than six weeks, sometimes for years. Chronic hives can be frustrating because they come and go and can interfere with sleep, work, or school. Hives affect how you look, and people may worry about being near you for fear that you have a contagious infection.",
"    </p>",
"    <p>",
"     However, it is important to remember that:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Hives are not contagious",
"      </li>",
"      <li>",
"       Chronic hives are rarely permanent; almost 50 percent of people are hive free within one year",
"      </li>",
"      <li>",
"       Chronic hives are rarely caused by allergies and are not life-threatening",
"      </li>",
"      <li>",
"       The bothersome symptoms of chronic hives are treatable in most people",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In most cases of chronic hives, the cause is unknown. Researchers suspect that problems in the immune system play a role.",
"    </p>",
"    <p>",
"     Hives can be a sign of several other medical or autoimmune conditions, including thyroid or liver diseases, chronic infections, or lupus. Most people with one of these conditions will have other symptoms, apart from the hives.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Physical hives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hives can be triggered by a variety of physical factors (see",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"      \"Physical urticarias\"",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Exposure to cold: The hives often appear as the cold skin warms again. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=see_link\">",
"        \"Cold urticaria\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Changes in body temperature or sweating: These hives are often tiny and numerous and appear on reddened skin.",
"      </li>",
"      <li>",
"       Vibration: Palms may become red, swollen, and itchy after holding onto the steering wheel of a car while driving.",
"      </li>",
"      <li>",
"       Pressure: Hives on the palms or the soles of the feet can occur hours after carrying heavy objects or walking long distances. Because the skin on the palms and soles is thick, these areas may appear reddened and swollen without clear hives.",
"      </li>",
"      <li>",
"       Exercise: Hives that appear during exercise can be a sign of a dangerous condition called exercise-induced anaphylaxis. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42709?source=see_link\">",
"        \"Exercise-induced anaphylaxis: Management and prognosis\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Sunlight or water: This is rare. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link\">",
"        \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Finally, there is a common condition called dermographism (literally \"skin writing\"). People with this condition develop reddened, raised lines if the skin is stroked firmly or scratched.",
"    </p>",
"    <p>",
"     Physical forms of hives tend to be long lasting and are considered a type of chronic hives.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      HIVES TESTING",
"     </span>",
"    </p>",
"    <p>",
"     Most people with hives do not need any testing. The diagnosis is usually based on your symptoms and a physical examination. However, tests may be recommended if hives do not resolve within six weeks. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"      \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Skin testing for food and drug sensitivities may be recommended if there are concerns about allergies as a cause of symptoms. This is usually done for people with acute hives; chronic hives are rarely caused by an allergy. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"      \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Blood tests are sometimes done if hives continue for several weeks. Blood tests can tell if there are signs of underlying diseases, such as liver or thyroid problems or an autoimmune disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Skin biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A skin biopsy (when a small sample of skin is removed) may help identify uncommon causes of hives. A skin biopsy may be recommended for people who have chronic hives along with other symptoms, such as persistent fever, painful hives, individual hives that last for days at a time, or hives associated with bruising of the skin. A skin biopsy may also be recommended for people who have other symptoms or abnormal blood tests.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      HIVES TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"      \"New onset urticaria\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"      \"Chronic urticaria: Standard management and patient education\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Avoid triggers",
"     </span>",
"     &nbsp;&mdash;&nbsp;The first treatment for hives is to figure out what is triggering the hives and then avoid that trigger. Even if you cannot figure out the trigger, hives usually disappear over days or weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Antihistamines",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antihistamines are medicines that can relieve itching. Most people with hives respond to antihistamines. You may need a relatively high dose or more than one type of antihistamine to control your symptoms.",
"    </p>",
"    <p>",
"     There are two main types of antihistamines. They differ in side effects, cost, how long the medicine lasts, and need for a prescription.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Older antihistamines &mdash; Older antihistamines start to work quickly and work well to relieve symptoms. The problem with older antihistamines is that you have to take a dose four to six times per day, and many people have bothersome side effects. These can include drowsiness, dry mouth, double or blurred vision, or difficulty urinating.",
"       <br/>",
"       <br/>",
"       Some of these side effects interfere with driving and tasks requiring quick reactions, similar to the effects of drinking alcohol. These medicines are therefore not recommended for people who plan to drive, pilot aircrafts or boats, or operate heavy machinery, or for people whose job performance may be otherwise affected. Starting the medicine at a low dose and gradually increasing the dose can help to ease side effects. The side effects usually get better if you take the medicine regularly over a period of days to weeks.",
"       <br/>",
"       <br/>",
"       The older antihistamines include:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Diphenhydramine (Benadryl&reg; and others)",
"      </li>",
"      <li>",
"       Chlorpheniramine (Chlor-Trimeton&reg; and others) &ndash; Chlorpheniramine appears to be safe in pregnant women.",
"      </li>",
"      <li>",
"       Hydroxyzine (Atarax&reg;, Vistaril&reg;, requires prescription)",
"      </li>",
"      <li>",
"       Cyproheptadine (Periactin&reg;, requires prescription)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Newer antihistamines &mdash; Newer antihistamines have fewer side effects than older antihistamines. Also, newer antihistamines have to be taken less often, usually once or twice per day. Examples include:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Loratadine (Claritin&reg; and generic)",
"      </li>",
"      <li>",
"       Cetirizine (Zyrtec&reg; and generic)",
"      </li>",
"      <li>",
"       Fexofenadine (Allegra&reg; and generic)",
"      </li>",
"      <li>",
"       Desloratadine (Clarinex&reg;, requires prescription)",
"      </li>",
"      <li>",
"       Levocetirizine (Xyzal&reg;, requires prescription)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Other antihistamines &mdash; There is another type of antihistamine that is commonly used to treat heartburn. Your doctor or nurse might recommend one of these medicines in combination with another antihistamine, if one medicine alone does not work for you. Examples of this type of antihistamine include:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Ranitidine (Zantac&reg;)",
"      </li>",
"      <li>",
"       Nizatidine (Axid&reg;)",
"      </li>",
"      <li>",
"       Famotidine (Pepcid&reg;)",
"      </li>",
"      <li>",
"       Cimetidine (Tagamet&reg;)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Doxepin &mdash; Doxepin (Sinequan&reg;) can sometimes relieve hives that do not respond to other treatments. However, doxepin causes significant drowsiness and is not recommended when driving or working. Doxepin is sometimes taken at bedtime to help people with severe hives get a better night's sleep.",
"      </li>",
"      <li>",
"       Ketotifen &mdash; Ketotifen is a medicine sometimes used to treat hives. Ketotifen is not available in the United States in pill form, but has been used for many years in Canada, Japan, and Europe.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Oral steroids",
"     </span>",
"     &nbsp;&mdash;&nbsp;A high dose of antihistamines is usually recommended before trying other treatments. However, oral steroids (glucocorticoids), such as prednisone, can help to relieve severe acute hives that do not get better with antihistamines. Once the hives have improved, the steroid dose is gradually lowered and then stopped.",
"    </p>",
"    <p>",
"     Oral steroids may be used temporarily to relieve chronic hives, but they should not be used for long-term treatment. This is because steroids can have serious side effects when taken for long periods of time (months or years).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Other medicines",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your hives do not get better with the treatments discussed above, other treatments are available. In this case, you should see a specialist (an allergist or a dermatologist).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3046387817\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/47/37617?source=see_link\">",
"      Patient information: Hives (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/31/1523?source=see_link\">",
"      Patient information: Angioedema (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/34/2594?source=see_link\">",
"      Patient information: Primary biliary cirrhosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/17/18706?source=see_link\">",
"      Patient information: Chronic hives (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/27/44466?source=see_link\">",
"      Patient information: Physical hives (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3046387834\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=see_link\">",
"      Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/22/18786?source=see_link\">",
"      Patient information: Bee and insect stings (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/44/19138?source=see_link\">",
"      Patient information: Fire ants (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/47/29429?source=see_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40681?source=see_link\">",
"      Allergic and asthmatic reactions to food additives",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=see_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38391?source=see_link\">",
"      An overview of angioedema: Pathogenesis and causes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35541?source=see_link\">",
"      Approach to dermatologic diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39286?source=see_link\">",
"      Bedbugs",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43556?source=see_link\">",
"      Chigger bites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/7/117?source=see_link\">",
"      Chronic urticaria: Standard management and patient education",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/12/5321?source=see_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/62/38888?source=see_link\">",
"      Differential diagnosis of anaphylaxis in children and adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"      Drug eruptions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"      New onset urticaria",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/60/32714?source=see_link\">",
"      Urticarial vasculitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24666?source=see_link\">",
"      Physical urticarias",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15721?source=see_link\">",
"      Cold urticaria",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42709?source=see_link\">",
"      Exercise-induced anaphylaxis: Management and prognosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/hives.html\">",
"        www.nlm.nih.gov/medlineplus/hives.html",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?2/45/2772/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?2/45/2772?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2772/abstract/1\">",
"      Zuberbier T. Urticaria. Allergy 2003; 58:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2772/abstract/2\">",
"      Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2772/abstract/3\">",
"      Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004; 114:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2772/abstract/4\">",
"      Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003; 3:363.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f2_45_2772=[""].join("\n");
var outline_f2_45_2772=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           HIVES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HIVES SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           TYPES OF HIVES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           HIVES TESTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           HIVES TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\" title=\"picture 1\">",
"           Hives PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/53/4944\" title=\"picture 2\">",
"           Acute urticaria child PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f2_45_2773="Immunohistochemistry showing fibronectin staining in glomerulus";
var content_f2_45_2773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F88601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F88601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunohistochemistry showing fibronectin staining in the glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunohistochemical staining of a glomerulus for fibronectin&nbsp;in a patient with fibronectin glomerulopathy. Fibronectin is deposited in the mesangium and along the capillary walls.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2773=[""].join("\n");
var outline_f2_45_2773=null;
var title_f2_45_2774="Formoterol and mometasone: Drug information";
var content_f2_45_2774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Formoterol and mometasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/4/3142?source=see_link\">",
"    see \"Formoterol and mometasone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/61/22485?source=see_link\">",
"    see \"Formoterol and mometasone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10379527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10356502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dulera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zenhale&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10379534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta;",
"      <sub>",
"       2",
"      </sub>",
"      Agonist, Long-Acting",
"     </li>",
"     <li>",
"      Beta;",
"      <sub>",
"       2",
"      </sub>",
"      -Adrenergic Agonist, Long-Acting",
"     </li>",
"     <li>",
"      Corticosteroid, Inhalant (Oral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10379580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Previous therapy included inhaled low-dose corticosteroids:",
"     </i>",
"     Canadian labeling (not in U.S. labeling): Mometasone 50 mcg/formoterol 5 mcg: Two inhalations twice daily. Maximum daily dose: 4 inhalations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Previous therapy included inhaled medium-dose corticosteroids:",
"     </i>",
"     Mometasone 100 mcg/formoterol 5 mcg: Two inhalations twice daily. Consider the higher dose combination for patients not adequately controlled on the lower combination following 1-2 weeks of therapy. Maximum daily dose: 4 inhalations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Previous therapy included inhaled high-dose corticosteroids:",
"     </i>",
"     Mometasone 200 mcg/formoterol 5 mcg: Two inhalations twice daily. Maximum daily dose: 4 inhalations",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10379604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/61/22485?source=see_link\">",
"      see \"Formoterol and mometasone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral inhalation: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10379605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F10379581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mometasone systemic exposure appears to increase with increasing extent of impairment; however, there is no dosage adjustment recommended in the manufacturer labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10379678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulera&reg;: Mometasone furoate 100 mcg and formoterol fumarate dihydrate  5 mcg per inhalation (8.8 g) [60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulera&reg;: Mometasone furoate 100 mcg and formoterol fumarate dihydrate  5 mcg per inhalation (13 g) [120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulera&reg;: Mometasone furoate 200 mcg and formoterol fumarate dihydrate  5 mcg per inhalation (8.8 g) [60 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dulera&reg;: Mometasone furoate 200 mcg and formoterol fumarate dihydrate  5 mcg per inhalation (13 g) [120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F12959475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zenhale&trade;: Mometasone furoate 50 mcg and formoterol fumarate dihydrate  5 mcg per inhalation [120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10379532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10379528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at  file://www.spfiles.com/mgdulera.pdf; must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10379606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to first use, inhaler must be primed by releasing 4 test sprays into the air; shake well before each spray. Inhaler must be reprimed if not used for &gt;5 days. Shake well before each use. Discard inhaler after the labeled number of inhalations have been used.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Delivery of dose: Instruct patient to place mouthpiece gently between teeth, closing lips around inhaler. Instruct patient to inhale deeply and hold breath held for 5-10 seconds. The amount of drug delivered is small, and the individual will not sense the medication as it is inhaled. Remove mouthpiece from mouth prior to exhalation. Patient should not breathe out through the mouthpiece. After use of the inhaler, patient should rinse mouth/oropharynx with water and spit out rinse solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10379537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment of asthma where combination therapy is indicated",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10379567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (&le;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (5%), dysphonia (4% to 5%), sinusitis (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reactions, angina pectoris, angioedema, asthma aggravation, atrial fibrillation, blood pressure increased, hyperglycemia, hypertension, hypokalemia, hypotension, oral candidiasis, pruritus, QT prolongation, rash, tachyarrhythmia, ventricular extrasystoles",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10379541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mometasone, formoterol, or any component of the formulation; need for acute bronchodilation (including status asthmaticus)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10379564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Do not use this product to transfer patients from oral corticosteroid therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma-related deaths:",
"     <b>",
"      [U.S. Boxed Warning]: Long-acting beta",
"      <sub>",
"       2",
"      </sub>",
"      -agonists (LABAs), such as formoterol, increase the risk of asthma-related deaths; mometasone and formoterol should only be used in patients not adequately controlled on a long-term asthma control medication (ie, inhaled corticosteroid) or whose disease severity requires initiation of two maintenance therapies.",
"     </b>",
"     In a large, randomized, placebo-controlled U.S. clinical trial (SMART, 2006), salmeterol was associated with an increase in asthma-related deaths (when added to usual asthma therapy); risk is considered a class effect among all LABAs. Data are not available to determine if the addition of an inhaled corticosteroid lessens this increased risk of death associated with LABA use. Assess patients at regular intervals once asthma control is maintained on combination therapy to determine if step-down therapy is appropriate (without loss of asthma control), and the patient can be maintained on an inhaled corticosteroid only. LABAs are not appropriate in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone density: Long-term use may decrease bone mineral density in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria. Close observation is required in patients with latent tuberculosis and/or TB reactivity. Restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral candidiasis: Infections with",
"     <i>",
"      Candida albicans",
"     </i>",
"     in the mouth and throat (thrush) have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vasculitis: Rare cases of vasculitis (Churg-Strauss syndrome) have been reported with use of inhaled corticosteroid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Appropriate use: Do",
"     <b>",
"      not",
"     </b>",
"     use for acute bronchospasm. Short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Do",
"     <b>",
"      not",
"     </b>",
"     initiate in patients with significantly worsening or acutely deteriorating asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia or hypertension or HF); beta agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may also increase risk of arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists may increase serum glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Use with caution in patients with hypokalemia; beta2-agonists may decrease serum potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with seizure disorders; beta agonists may result in CNS stimulation/excitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: LABAs may increase the risk of asthma-related hospitalization in pediatric and adolescent patients.",
"     </b>",
"     Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient information: Patients must be instructed to seek medical attention in cases where acute symptoms are not relieved by short-acting beta-agonist (not formoterol) or a previous level of response is diminished. Medical evaluation must not be delayed. Patients using inhaled, short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists should be instructed to discontinue routine use of these medications prior to beginning treatment with Dulera&reg;; short-acting agents should be reserved for symptomatic relief of acute symptoms. Patients should not use additional long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonists.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F10379572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10486859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F10379538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10379539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10379540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Excretion in breast milk unknown/use caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mometasone: Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Dulera Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-5 mcg/ACT (8.8 g): $181.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200-5 mcg/ACT (8.8 g): $181.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10379668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow meter, and/or other pulmonary function tests; monitor growth in pediatric patients, symptom relief, monitor for increased use if short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic agonists (may be a sign of asthma deterioration)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10379575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Formoterol relaxes bronchial smooth muscle by selective action on beta",
"     <sub>",
"      2",
"     </sub>",
"     receptors with little effect on heart rate. Formoterol has a long-acting effect. Mometasone is a corticosteroid which controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes/fibroblasts, and reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10379577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15580 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2774=[""].join("\n");
var outline_f2_45_2774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379527\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10356502\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817177\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379534\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379580\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379604\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379605\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379581\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379678\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12959475\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379532\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379528\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379606\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379537\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379567\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379541\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379564\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379572\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10486859\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379538\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379539\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379540\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322858\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379668\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379575\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10379577\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15580\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/15580|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/4/3142?source=related_link\">",
"      Formoterol and mometasone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/61/22485?source=related_link\">",
"      Formoterol and mometasone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_45_2775="Felodipine: Drug information";
var content_f2_45_2775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Felodipine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1221?source=see_link\">",
"    see \"Felodipine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/48/8966?source=see_link\">",
"    see \"Felodipine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Plendil&reg;;",
"     </li>",
"     <li>",
"      Renedil&reg;;",
"     </li>",
"     <li>",
"      Sandoz-Felodipine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Dihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F170354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension: Oral: 2.5-10 mg once daily; increase by 5 mg at 2-week intervals, as needed, to a maximum of 20 mg/day; usual dose range (JNC 7): 2.5-20 mg once daily.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4473156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/48/8966?source=see_link\">",
"      see \"Felodipine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension (unlabeled use): Oral: Initial: 2.5 mg once daily; maximum: 10 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg, 2.5 mg once daily) and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15881414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F170356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: 2.5 mg/day; monitor blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 2.5 mg, 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F170328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Swallow tablet whole; tablet should not be divided, crushed, or chewed. May be administered without food or with a small meal that is low in fat and carbohydrates.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F4589527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pediatric hypertension",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F170402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Plendil&reg; may be confused with Isordil&reg;, pindolol, Pletal&reg;, PriLOSEC&reg;, Prinivil&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (11% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%: Cardiovascular: Peripheral edema (2% to 17%), tachycardia (0.4% to 2.5%), flushing (4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Angina, angioedema, anxiety, arrhythmia, CHF, CVA, libido decreased, depression, dizziness, gingival hyperplasia, dyspnea, dysuria, gynecomastia, hypotension, impotence, insomnia, irritability, leukocytoclastic vasculitis, MI, nervousness, paresthesia, somnolence, syncope, urticaria, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to felodipine, any component of the formulation, or other calcium channel blocker",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina/MI: Increased angina and/or MI has occurred with initiation or dosage titration of dihydropyridine calcium channel blockers; reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease especially in the absence of concurrent beta-blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral edema: The most common side effect is peripheral edema (dose dependent); occurs within 2-3 weeks of starting therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with extreme caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with heart failure. Safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may require lower starting dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Initiate at a lower dose in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Titration: Dosage titration should occur after 14 days on a given dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F170389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Calcium Channel Blockers (Dihydropyridine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Calcium Channel Blockers (Dihydropyridine). Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Felodipine. Management: Monitor hemodynamic response to felodipine closely in patients who consume grapefruit juice.  Felodipine dose adjustment and/or modification of grapefruit juice ingestion may be needed. Felodipine Canadian labeling recommends avoiding grapefruit juice.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Felodipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F170345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol increases felodipine absorption. Management: Monitor for a greater hypotensive effect if ethanol is consumed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Compared to a fasted state, felodipine peak plasma concentrations are increased up to twofold when taken after a meal high in fat or carbohydrates. Grapefruit juice similarly increases felodipine C",
"     <sub>",
"      max",
"     </sub>",
"     by twofold. Increased therapeutic and vasodilator side effects, including severe hypotension and myocardial ischemia, may occur. Management: May be taken with a small meal that is low in fat and carbohydrates; avoid grapefruit juice during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease felodipine levels. Dong quai has estrogenic activity. Some herbal medications may worsen hypertension (eg, ephedra); garlic may have additional antihypertensive effects. Management: Avoid dong quai if using for hypertension. Avoid ephedra, yohimbe, ginseng, and garlic.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F170335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F170359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16354859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if felodipine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F170336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with a small meal that is low in fat and carbohydrates.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F170334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Felodipine ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $151.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $151.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $271.52",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F170337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AGON SR (NZ);",
"     </li>",
"     <li>",
"      Dilahex (PH);",
"     </li>",
"     <li>",
"      Dilofen ER (PH);",
"     </li>",
"     <li>",
"      Dilopin (KP);",
"     </li>",
"     <li>",
"      Fedil (TW);",
"     </li>",
"     <li>",
"      Fedil SR (TH);",
"     </li>",
"     <li>",
"      Felo ER (NZ, TW);",
"     </li>",
"     <li>",
"      Felocor (DE);",
"     </li>",
"     <li>",
"      Felocor Retardtab (DE);",
"     </li>",
"     <li>",
"      Felodil XR (AU);",
"     </li>",
"     <li>",
"      Felodin ER (PH);",
"     </li>",
"     <li>",
"      Felodur ER (AU);",
"     </li>",
"     <li>",
"      Felogamma Retard (DE);",
"     </li>",
"     <li>",
"      Felogard (IN);",
"     </li>",
"     <li>",
"      Felopine 5 (TH);",
"     </li>",
"     <li>",
"      Felopine-SR (TW);",
"     </li>",
"     <li>",
"      Feloten (TH);",
"     </li>",
"     <li>",
"      Felpin (TW);",
"     </li>",
"     <li>",
"      Felpin E.R. (PH);",
"     </li>",
"     <li>",
"      Fensel (ES);",
"     </li>",
"     <li>",
"      Flodil LP (FR);",
"     </li>",
"     <li>",
"      Hidipine (KP);",
"     </li>",
"     <li>",
"      Hydac (FI, SE);",
"     </li>",
"     <li>",
"      Keliping (CL);",
"     </li>",
"     <li>",
"      Keydipin ER (KP);",
"     </li>",
"     <li>",
"      Lodil (KP);",
"     </li>",
"     <li>",
"      Lodipin ER (KP);",
"     </li>",
"     <li>",
"      Lodistad MR (PH);",
"     </li>",
"     <li>",
"      Modip (DE);",
"     </li>",
"     <li>",
"      Munobal (DE, KP, MX, VE);",
"     </li>",
"     <li>",
"      Munobal Retard (AT, DE);",
"     </li>",
"     <li>",
"      Nirmadil (ID);",
"     </li>",
"     <li>",
"      Penedil (IL);",
"     </li>",
"     <li>",
"      Perfudal (ES);",
"     </li>",
"     <li>",
"      Plendil (AE, AR, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CR, CY, CZ, DK, DO, EC, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, IE, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, OM, PA, PE, PK, PL, PR, PY, QA, RU, SA, SC, SD, SE, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Plendil Depottab (NO);",
"     </li>",
"     <li>",
"      Plendil ER (AU, NZ, PH);",
"     </li>",
"     <li>",
"      Plendil Retard (AT);",
"     </li>",
"     <li>",
"      Preslow (ES, PT);",
"     </li>",
"     <li>",
"      Renedil (BE, LU);",
"     </li>",
"     <li>",
"      Splendil (BR, CN, JP);",
"     </li>",
"     <li>",
"      Splendil ER (KP);",
"     </li>",
"     <li>",
"      Stapin ER (KP);",
"     </li>",
"     <li>",
"      Topidil (TH);",
"     </li>",
"     <li>",
"      Vaspine ER (KP);",
"     </li>",
"     <li>",
"      Versant XR (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ions from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antihypertensive: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of antihypertensive effect: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 100%; Absolute: 20% due to first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; CYP3A4 substrate (major); extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Immediate release: 11-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (70% as metabolites); feces 10%",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/45/2775/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/45/2775/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN, Ziesche S, Smith R, et al, &ldquo;Effect of the Calcium Antagonist Felodipine as Supplementary Vasodilator Therapy in Patients With Chronic Heart Failure Treated With Enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 96(3):856-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/45/2775/abstract-text/9264493/pubmed\" id=\"9264493\" target=\"_blank\">",
"        9264493",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/45/2775/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/45/2775/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/45/2775/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/45/2775/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steele RM, Schuna AA, and Schreiber RT, &ldquo;Calcium Antagonist-Induced Gingival Hyperplasia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 120(8):663-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?2/45/2775/abstract-text/8135450/pubmed\" id=\"8135450\" target=\"_blank\">",
"        8135450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8438 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2775=[""].join("\n");
var outline_f2_45_2775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170350\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170395\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170354\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4473156\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170355\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881414\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170356\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170324\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170311\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170328\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170327\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4589527\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170402\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170393\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170331\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170315\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170389\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170320\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170345\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170321\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170335\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170359\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16354859\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170336\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170334\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170337\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170314\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170330\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8438|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/12/1221?source=related_link\">",
"      Felodipine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/48/8966?source=related_link\">",
"      Felodipine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_45_2776="Haloed lymphocytes of MF";
var content_f2_45_2776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F83484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F83484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Haloed lymphocytes of mycosis fungoides",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin biopsy from a patient with&nbsp;mycosis fungoides shows many single haloed lymphocytes. Hematoxylin and eosin, 40x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2776=[""].join("\n");
var outline_f2_45_2776=null;
var title_f2_45_2777="Protein restriction and progression of chronic kidney disease";
var content_f2_45_2777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Protein restriction and progression of chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/45/2777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/45/2777/contributors\">",
"     Ajay K Singh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/45/2777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/45/2777/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?2/45/2777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?2/45/2777/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?2/45/2777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive studies in animals and preliminary studies in humans suggest that progression of a variety of chronic kidney diseases (CKD) may be largely due to secondary hemodynamic and metabolic factors, rather than the activity of the underlying disorder. Identification of these factors, such as intraglomerular hypertension and glomerular hypertrophy, is clinically important because they can be treated, which may prevent or minimize further glomerular injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a variety of animal models (such as subtotal nephrectomy and diabetic nephropathy), lowering protein intake protects against the development of glomerular scarring (called glomerulosclerosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This effect is mediated, in part, by changes in glomerular arteriolar resistance, leading to a reduction in intraglomerular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and decreased glomerular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dietary protein restriction may also be beneficial by exerting nonhemodynamic effects. In experimental focal segmental glomerulosclerosis, for example, a very low protein diet can markedly reduce glomerular scarring in conjunction with decreased expression of the cytokines transforming growth factor (TGF) beta-1 and platelet-derived growth factor (PDGF), and of glomerular genes regulating the synthesis of excess matrix that contributes to the sclerotic lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The mechanism by which protein intake affects cytokine expression is unclear, but the net effect may be preserved glomerular filtration due to diminished matrix accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .) The applicability of these findings to humans remains unproven.",
"   </p>",
"   <p>",
"    Studies in humans indicate that an increase in the glomerular filtration rate (GFR) can be induced by animal protein and by amino acid mixtures [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]; in comparison, vegetable protein and egg whites alone produce little or no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Why the latter sources of protein have little hemodynamic activity is not clear, but lower concentrations of the amino acids that cause renal vasodilatation (such as glycine and alanine) and lesser stimulation of vasodilator prostaglandins may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of protein restriction, including mechanisms of action, in slowing the progression of CKD is presented in this topic review. A detailed discussion of the use of antihypertensive therapy in CKD is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF PROTEIN-INDUCED HYPERFILTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which dietary protein or amino acids affect renal hemodynamics is not completely understood. Two major theories have been proposed, including the altered release of a hormone or hormones and an intrarenal effect involving sodium reabsorption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tubuloglomerular feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hormonal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced secretion of glucagons, a direct renal vasodilator, may be a mediator of protein-induced hyperfiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. A high protein diet also increases the release of at least two other hormones that can raise the GFR, including insulin-like growth factor I (IGF-I) and kinins [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. IGF-1 is a direct renal vasodilator that can increase both renal blood flow and the GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition to a possible role in protein-induced hyperfiltration, IGF-1 may play an important role in the hyperfiltration and glomerular hypertrophy observed in type 1 diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=see_link\">",
"     \"Overview of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The renin-angiotensin system may also modulate the effect of protein on glomerular filtration. Angiotensin II leads to a preferential increase in efferent arteriolar resistance, causing an increase in intraglomerular pressure and hyperfiltration. Lowering angiotensin II production induces efferent dilatation, which decreases intraglomerular pressure and perhaps the GFR. However, there are conflicting data on the effect of a low protein diet on renal renin release. Both a reduction in renin gene expression (which could contribute to the protective effect of a low protein diet in renal disease) and an increase in gene expression have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/6,12\">",
"     6,12",
"    </a>",
"    ]. A review of the potential beneficial effects of angiotensin converting enzyme inhibitors is available in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intrarenal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrarenal mechanisms, including tubuloglomerular feedback, may contribute to protein-induced hyperfiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. An increase in the filtered load of amino acids may enhance proximal sodium reabsorption via sodium-amino acid cotransporters in the proximal tubule. The ensuing decrease in sodium chloride delivery to the macula densa may then activate tubuloglomerular feedback, leading to an elevation in GFR in an appropriate attempt to restore macula densa delivery to normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=see_link&amp;anchor=H4#H4\">",
"     \"Chapter 2D: Regulation of GFR and renal plasma flow\", section on 'Tubuloglomerular feedback'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein restriction also limits phosphorus intake, which may contribute to a beneficial effect on disease progression. In rats, protein restriction suppresses the expression of profibrotic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/13\">",
"     13",
"    </a>",
"    ], and reduced the number of infiltrating T-cells in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/14\">",
"     14",
"    </a>",
"    ], both of which may retard the progression of kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROTEIN RESTRICTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple well-designed randomized controlled human trials have evaluated both the efficacy and safety of protein restriction in patients with progressive CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. Protein restriction to approximately 0.6 to 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day is associated with a modest but not significant benefit of protein restriction on progression of renal disease. It is generally well tolerated and does not lead to malnutrition in patients with CKD providing caloric goals are met, dietary protein is of high biologic value, and metabolic acidosis is avoided.",
"   </p>",
"   <p>",
"    Therefore, we agree with the 2012 KDIGO guidelines that suggest the use of a lower high quality protein diet of 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day among select predialysis patients who are highly motivated to follow such a diet [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/20\">",
"     20",
"    </a>",
"    ]. However, the adoption of this diet should NOT preclude the initiation of dialysis among patients with severe CKD, if indicated, and should be undertaken under the supervision of a dietician with experience in caring for patients with reduced renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"     \"Indications for initiation of dialysis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical trials evaluating efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relatively small studies have suggested that a low protein diet may protect against progression of CKD in at least some diseases, such as diabetic nephropathy and chronic glomerular diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. In two trials in diabetic nephropathy, for example, the rate of decline in GFR was slowed by as much as 75 percent with dietary protein restriction (",
"    <a class=\"graphic graphic_figure graphicRef50017 \" href=\"UTD.htm?15/13/15581\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .) In one small study, even patients with an initial GFR as low as 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    appeared to benefit (",
"    <a class=\"graphic graphic_figure graphicRef71070 \" href=\"UTD.htm?28/31/29181\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these positive results, a much larger controlled trial (Northern Italian Cooperative Study Group) involving 456 Italian patients with a variety of renal diseases found that a low protein diet produced only a small, not statistically significant trend toward benefit at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/25\">",
"     25",
"    </a>",
"    ]. There were, however, two potential problems with this study: the GFR was measured indirectly by the often inaccurate creatinine clearance (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35190?source=see_link\">",
"     \"Calculation of the creatinine clearance\"",
"    </a>",
"    ); and, more importantly, noncompliance with protein restriction minimized the difference in dietary intake between control and treated groups. Protein intake (as estimated from the formula derived below) has been close to 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day in the control group in most studies. Whereas protein intake was reduced by 29 to 43 percent in the treated group in the smaller successful trials [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/21-23\">",
"     21-23",
"    </a>",
"    ], it was reduced by only 16 percent in the Italian trial [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/25\">",
"     25",
"    </a>",
"    ]. This difficulty with compliance occurred despite the availability of much greater dietary counseling and monitoring than is available to the typical practitioner.",
"   </p>",
"   <p>",
"    Subsequently, in the largest trial to date, the Modification of Diet in Renal Disease (MDRD) study analyzed 585 patients with nondiabetic CKD and a mean GFR of 39",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (all patients with GFR less than 55",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients were randomly assigned to protein intakes of 1.3 or 0.58",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day with or without aggressive blood pressure control and followed for a mean of 2.2 years. The achieved protein intake in the low protein group was between 0.6 to 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. Despite good compliance, there appeared to be little overall benefit with the low protein diet. A biphasic response was noted: patients treated with protein restriction had a greater fall in GFR in the first four months (that may have reflected a reduction in intraglomerular pressure), followed by somewhat slower progression over the ensuing months (2.8 versus 3.9",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year) (",
"    <a class=\"graphic graphic_figure graphicRef59277 \" href=\"UTD.htm?34/40/35469\">",
"     figure 3",
"    </a>",
"    ). However, even in this later phase, the absolute benefit was still small at only 1.1",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per year. A similar lack of substantial benefit was noted in a second part of this study involving 255 patients with more advanced disease (mean GFR 19",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) who were randomized to a low protein diet or a very low protein diet (0.3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) with a keto acid-amino acid supplement. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Effects of a very low protein diet'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A long-term follow-up analysis of the MDRD study was subsequently published [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/27\">",
"     27",
"    </a>",
"    ]. In this 12-year study (1989 to 2000), the authors evaluated outcomes during the first six years after the trial ended (1989 to 1994), the next six year period (1995 to 2000), and the total 12-year period. Analysis of outcomes after the first six years revealed a small but significant benefit of low-protein intake on renal failure and all-cause mortality (hazard ratios of 0.68, CI 0.51-0.93 and 0.66, CI 0.50-0.87, respectively). However, there was no benefit of protein restriction when outcomes between 6 and 12 years were analyzed.",
"   </p>",
"   <p>",
"    A major limitation of this analysis included lack of data for dietary intake after the completion of the study. Thus, it is possible that the lack of effect of the low protein diet observed beyond six years reflected a decrease in adherence to the prescribed diet. These data suggest the need for a longer follow-up period for future studies designed to assess the effects of protein restriction intervention.",
"   </p>",
"   <p>",
"    The MDRD study and the Northern Italian Cooperative Study raise the question of why human trials have been unable to replicate the robust benefit observed in animal models. A number of factors may play a contributory role:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both control and experimental groups had excellent blood pressure control and many were being treated with ACE inhibitors. The mean blood pressure in the MDRD study was",
"      <span class=\"nowrap\">",
"       131/81",
"      </span>",
"      at baseline, and 44 percent of patients were treated with an ACE inhibitor during the study. In this setting, in which hemodynamically-mediated injury should already be minimized, it may be difficult to demonstrate further benefit with dietary protein restriction. The observation that the rate of decline in GFR was only 3.9",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year in the control group is compatible with this hypothesis.",
"     </li>",
"     <li>",
"      The type of underlying disease might be important (see below). The MDRD trial, for example, included almost no patients with diabetic nephropathy (the group that might be most likely to benefit) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/21,22\">",
"       21,22",
"      </a>",
"      ], while 24 percent of patients had polycystic kidney disease (a disorder in which there is little evidence of hemodynamically-mediated injury). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=see_link\">",
"       \"Course and treatment of autosomal dominant polycystic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The control groups in the large Italian and MDRD studies ingested 1.0 and 1.1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of protein per day [",
"      <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Therefore, it is possible that higher levels of protein intake than these might be deleterious.",
"     </li>",
"     <li>",
"      The duration of study during which protein restriction was rigorously maintained may have been too short to reveal a beneficial effect of protein restriction.",
"     </li>",
"     <li>",
"      Some of the MDRD investigators have proposed that the seemingly small benefit from protein restriction may be clinically important [",
"      <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/28\">",
"       28",
"      </a>",
"      ]. According to this reasoning, a patient with a GFR of 40",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      who is losing 4",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year will require dialysis in about eight years. However, if the rate of fall were only 3",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year, then 11 years would be required to reach the same end-point. Thus, the absolute benefit would be three years without dialysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later, smaller trial of 128 patients also provided evidence of modest benefit from dietary protein restriction in nondiabetic CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/29\">",
"     29",
"    </a>",
"    ]. The less accurate creatinine clearance was used in this study and, at 2.3 years, the likelihood of more than a 50 percent reduction in creatinine clearance was 40 percent in the control group (mean protein intake 1.06",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) versus 29 percent in the treatment group (mean protein intake 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day, higher than the desired level of 0.6",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meta-analyses and systematic reviews",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several meta-analyses have examined the relationship between dietary protein restriction and the initiation of renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/30-35\">",
"     30-35",
"    </a>",
"    ]. A 2006 systematic review evaluated eight randomized controlled trials that compared low protein diets (0.3 to 0.6",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) with standard protein intake (&gt;0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) among 1524 patients with nondiabetic CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/33\">",
"     33",
"    </a>",
"    ]. Compared with standard protein intake, a low protein diet was associated with a decreased risk of need for dialysis, kidney transplantation, or death during follow-up (RR 0.69, 95% CI 0.56-0.86).",
"   </p>",
"   <p>",
"    However, these studies were primarily performed during a period prior to the current practice of aggressive blood pressure lowering and the administration of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. As a result, it is unclear if a low protein diet provides added renal protection to that obtained with the current standard approach [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cochrane review that was first published in 2000 and updated in 2007 analyzed nine randomized controlled trials and three before and after studies that evaluated protein-restricted diets in type 1 and type 2 diabetic CKD patients who were followed for at least four months. The authors concluded that there was modest but not significant benefit of protein restriction on progression of renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the studies had variable limits for protein restriction, heterogeneous follow-up, and did not report on quality of life.",
"   </p>",
"   <p>",
"    A Cochrane review published in 2009 that examined studies in nondiabetic adults showed a significant decrease in renal death, defined as death due to any cause or the need to start dialysis associated with a low protein diet [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/35\">",
"     35",
"    </a>",
"    ]. However there was marked heterogeneity in the degree of protein restriction used in the studies. A sub-analysis restricted to studies that used a moderate protein restriction (defined as 0.6",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day, three studies) showed no benefit.",
"   </p>",
"   <p>",
"    A 2012 meta-analysis that included six randomized trials found no reduction in mortality (relative risk 0.58, 95% CI 0.29-1.16) or ESRD (relative risk 1.62, 95% CI 0.62-4.21) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/37\">",
"     37",
"    </a>",
"    ]. However, only a small number of events occurred and the confidence intervals were wide for both outcomes.",
"   </p>",
"   <p>",
"    Variability in the stage of CKD, the degree of proteinuria, or in the type of protein provided may also have affected the outcomes of the various studies, although these data were not provided. Most of the included studies were of short duration which limits the interpretation of the meta-analysis.",
"   </p>",
"   <p>",
"    Nevertheless, these studies provide some evidence that a low protein diet may benefit some patients with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/36,38\">",
"     36,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effects of a very low protein diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited number of studies have evaluated the effects of a very low protein diet in patients with significant proteinuria or reduced GFR. One study evaluated the effects of a very low protein diet (0.3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day supplemented with 10 to 20",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of essential amino acids), which was administered for an average of ten months in 16 patients with the nephrotic syndrome caused by various different etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/39\">",
"     39",
"    </a>",
"    ]. Eleven of the 16 patients with clearances below 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    upon entrance into the study exhibited modest improvement with treatment, but all eventually required dialysis. Among the remaining five patients with clearances greater than 30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    however, dietary treatment for 3 to 14 months resulted in several beneficial effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased proteinuria (9.3 versus 1.9",
"      <span class=\"nowrap\">",
"       g/day).",
"      </span>",
"     </li>",
"     <li>",
"      Increased serum albumin concentration (2.5 versus 3.8",
"      <span class=\"nowrap\">",
"       g/dL).",
"      </span>",
"     </li>",
"     <li>",
"      Increased GFR (52 versus 70",
"      <span class=\"nowrap\">",
"       mL/min).",
"      </span>",
"     </li>",
"     <li>",
"      Upon resumption of a relatively normal diet, four of the five patients continued to remain in clinical remission (or near-remission) at a follow-up of 6 to 24 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The underlying cause(s) of nephrotic syndrome in all five of these patients was either focal segmental glomerulosclerosis, diabetic nephropathy, or both, disorders in which a spontaneous increase in clearance and resolution of the nephrotic syndrome is rarely (if ever) observed.",
"   </p>",
"   <p>",
"    The mechanism for these observations remains unclear. These striking results must be verified in larger, controlled studies prior to any possible change in our recommendations concerning the use of very low protein diets in patients with the nephrotic syndrome (see below).",
"   </p>",
"   <p>",
"    Some [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/26,42\">",
"     26,42",
"    </a>",
"    ], studies have suggested that a very low protein diet may help delay the requirement for renal replacement therapy among patients with near-end-stage renal failure (GFR of less than 6 to 10",
"    <span class=\"nowrap\">",
"     mL/min).",
"    </span>",
"   </p>",
"   <p>",
"    In one multicenter Italian study, 112 elderly nondialysis patients (age greater than 70 years) with end-stage renal disease (GFR of 5 to 7",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    were randomly assigned to dialysis or a very low protein diet (protein at 0.3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day; 35",
"    <span class=\"nowrap\">",
"     kcals/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/41\">",
"     41",
"    </a>",
"    ]. At a median follow-up of 26.5 months, both groups had similar mortality rates, while the rate of hospitalization was higher among those assigned to dialysis. Forty patients assigned to the diet group eventually required dialysis initiation after a median of 9.8 months due to hyperkalemia and volume overload. Patients with diabetes or nephrotic range proteinuria were excluded from this study, which limits its applicability to a general population.",
"   </p>",
"   <p>",
"    However, the MDRD study that was cited previously showed that a very low protein diet provided no benefit in delaying progression of renal disease over the long term among patients with advanced CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/26,42\">",
"     26,42",
"    </a>",
"    ]. The MDRD study included 255 patients with GFR 13 to 24",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 who were randomly assigned to either a low protein diet or a very low protein diet (0.3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) with a keto acid-amino acid supplement. Among patients assigned to the very low protein diet, no benefit was observed in either the time to end-stage renal disease or overall mortality at a mean follow-up of 2.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/26\">",
"     26",
"    </a>",
"    ]. A follow-up of the MDRD study at twelve years also showed no benefit to the very low protein diet in delaying the progression of kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important limitation of the observations at twelve years is that measurements of protein intake or nutritional measurements were not performed beyond nine months after the original MDRD study ended; the number of patients that continued the prescribed diet is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cochrane review suggested a benefit of a very low protein diet [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/35\">",
"     35",
"    </a>",
"    ]. Analysis of 7 studies that compared protein intake ranging from 0.3 to 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day versus a higher or unrestricted protein intake showed a decrease in renal death (defined as death due to any cause or the need to start dialysis) associated with protein restriction (RR 0.63, 95% CI 0.48-0.83). However, as discussed in the following section, very low protein diets have been associated with increased mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional studies in patients with CKD suggest that protein intake can be safely lowered to 0.6",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. However, a very low protein diet has been associated with increased mortality over the long term [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety profile of a low protein diet was assessed in an analysis of patients who were enrolled in the MDRD study [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients were randomly assigned to a standard protein diet (1.3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day), a low protein diet (0.58",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day), or a very low protein diet (0.3",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day supplemented with a ketoacid-amino acid mixture at 0.28",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day) based upon their GFR. Patients assigned to the low protein diet achieved a protein intake between 0.6 to 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. Patients assigned to the very low protein diet achieved a protein intake between 0.4 to 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p>",
"    At a mean follow-up of 2.2 years, a low protein intake was not associated with increased rates of mortality, hospitalization, or malnutrition.",
"   </p>",
"   <p>",
"    Lower levels of protein ingestion were associated with diminished energy intake and significant, but small, absolute declines in serum transferrin, body weight, percent body fat, and arm muscle area at a mean follow-up of 2.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/16\">",
"     16",
"    </a>",
"    ]. A twelve year follow-up of the MDRD study showed an increase risk of death among patients who received the very low protein diet compared to patients who received the low protein diet (hazard ratio 1.92, 95% CI 1.15-32) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/42\">",
"     42",
"    </a>",
"    ]. An important limitation of the observations at twelve years is that measurements of protein intake or nutritional measurements were not performed beyond nine months after the original MDRD study ended; the number of patients that continued the prescribed diet is not known [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/43\">",
"     43",
"    </a>",
"    ]. Despite this limitation, these observations suggest that important long-term safety risks are associated with the very low protein diet among patients with advanced CKD.",
"   </p>",
"   <p>",
"    As a result, a modest protein restriction to 0.6 to 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day appears to be safe. Significant health risks are associated with more severe restrictions over the long term. Careful nutritional monitoring of all CKD patients must be maintained if protein-restricted diets are prescribed.",
"   </p>",
"   <p>",
"    Three conditions must be met to avoid malnutrition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adequate caloric intake must be maintained.",
"     </li>",
"     <li>",
"      At least 60 percent of the ingested protein must be of high biologic value or contain a high percentage of essential amino acids (",
"      <a class=\"graphic graphic_table graphicRef67821 \" href=\"UTD.htm?24/16/24844\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stimulation of skeletal muscle protein breakdown should be prevented to limit net nitrogen loss. Metabolic acidosis should also be treated since metabolic acidosis stimulates skeletal muscle protein breakdown [",
"      <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/15,44\">",
"       15,44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link\">",
"       \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"      </a>",
"      .) A protein-restricted diet may, of itself, help to prevent metabolic acidosis. A post hoc analysis of the MDRD study showed that a reduction in protein intake resulted in increased serum CO2 after one year of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical trials evaluating efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, resistance training, properly supervised, may help maintain muscle mass [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monitoring nutritional adequacy in CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfortunately, there is no single optimal laboratory test to assess and monitor nutritional adequacy in CKD patients. The International Society of Renal Nutrition and Metabolism (ISRNM) convened an expert panel and published their recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/47\">",
"     47",
"    </a>",
"    ]. The panel coined the term \"kidney disease wasting,\" which refers to the occurrence of protein-energy malnutrition (loss of body protein mass and fuel reserve) in CKD or acute kidney injury regardless of the cause.",
"   </p>",
"   <p>",
"    Protein-energy wasting can be diagnosed if three characteristics are present [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low serum albumin, pre-albumin or cholesterol",
"     </li>",
"     <li>",
"      Reduced body mass (low or reduced body or fat mass or weight loss with reduced intake of protein and energy)",
"     </li>",
"     <li>",
"      Reduced muscle mass (muscle wasting or sarcopenia, reduced mid-arm muscle circumference)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serum transferrin, which is used as a marker of protein adequacy in general population, is not useful in CKD patients due to underlying anemia in the latter group. Measurements of inflammatory markers (eg, C-reactive protein, interleukin-6, etc.) alone or in combination with albumin or pre-albumin are also not recommended at this time to guide the nutritional status of patients with CKD.",
"   </p>",
"   <p>",
"    Patients with CKD who are on a protein restricted diet should be carefully monitored with close follow-up every three to six months for adequate caloric intake and evidence of protein malnutrition. We usually follow the body weight as well as serum albumin, pre-albumin, and cholesterol. More frequent monitoring (ie, monthly) may be necessary in patients with advanced CKD (ie, stages 4 and 5).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Estimating protein intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compliance with dietary protein restriction can be estimated from a 24-hour urine collection, providing daily intake is relatively constant and the patient is in a steady state (as evidenced by a stable BUN and body weight) [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/15,48\">",
"     15,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this setting, urinary nitrogen excretion is roughly equal to nitrogen intake. The former can be estimated from:",
"   </p>",
"   <p>",
"    &nbsp;Urinary nitrogen excretion &nbsp; = &nbsp; Urine urea nitrogen &nbsp; + &nbsp; Nonurea nitrogen",
"   </p>",
"   <p>",
"    Nonurea nitrogen excretion is relatively constant, averaging 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Moderate urinary protein loss can be ignored, but each gram excreted above 5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    should be added to the above formula.",
"   </p>",
"   <p>",
"    Each gram of nitrogen is derived from 6.25 g of protein. Thus,",
"   </p>",
"   <p>",
"    &nbsp;Estimated protein intake &nbsp; = &nbsp; 6.25 (Urine urea nitrogen &nbsp;+ &nbsp;30",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"   </p>",
"   <p>",
"    If, for example, 24-hour urine urea nitrogen excretion is 8.2 g in a 60 kg woman excreting 3.5 g of protein per day, then:",
"   </p>",
"   <p>",
"    &nbsp;Estimated protein intake &nbsp; = &nbsp; 6.25 (8.2 &nbsp;+ &nbsp;1.8) &nbsp; = &nbsp; 62.5 g",
"   </p>",
"   <p>",
"    Thus, protein intake is approximately 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NEPHROTIC SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of a low protein diet in nephrotic syndrome is uncertain. In some experimental models of nephrotic syndrome, the institution of a low protein diet diminished hepatic albumin synthesis, which suggests protein deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, in the same study, a low protein diet also decreased protein excretion, presumably due to a fall in intraglomerular pressure. The net effect of these opposing factors was no change in the plasma albumin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Overall, studies have not demonstrated conclusive evidence of malnutrition with protein restriction in moderately nephrotic animals [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study examined this issue in five stable patients with nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?2/45/2777/abstract/52\">",
"     52",
"    </a>",
"    ]. Despite moderate proteinuria that averaged 7.2",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    nitrogen balance was maintained on a diet that provided 0.8",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day of protein plus 1 g of protein for each gram of proteinuria and 35",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day. Positive nitrogen balance was maintained by the inhibition of amino acid oxidation and protein degradation and by stimulation of protein synthesis during feeding.",
"   </p>",
"   <p>",
"    These data suggest that protein restriction can be safely implemented in patients with moderate proteinuria providing adequate caloric intake is maintained.",
"   </p>",
"   <p>",
"    However, these data do not define the minimum safe protein intake nor do they prove that supplementing protein intake for the degree of proteinuria is necessary. In addition, the safety of protein restriction in patients with massive proteinuria (&gt;15",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or concurrent catabolic states (eg, due to corticosteroids or systemic lupus erythematosus) remains uncertain. Thus, we do not use protein restriction for patients with nephrotic syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary protein restriction may protect against the progression of CKD by hemodynamically mediated reductions in intraglomerular pressure and by changes in cytokine expression and matrix synthesis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.) The hemodynamic effects of protein-induced hyperfiltration may be due to changes in hormones (such as glucagon and insulin-like growth factor-1), alterations in renin-angiotensin system, and intrarenal effects, including tubuloglomerular feedback. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of protein-induced hyperfiltration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefits of dietary protein restriction to approximately 0.6 to 0.8",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      per day on the progression of CKD in humans remain controversial. Current data suggest that, at best, a small reduction in the rate of decline of glomerular filtration rate (GFR) may be observed with a low protein diet. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical trials evaluating efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Meta-analyses and systematic reviews'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with glomerular filtration rates less than 60",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      we suggest the intake of approximately 0.8",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      of high biologic value protein per day rather than higher protein values (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This diet should also be administered in combination with other measures to slow the rate of progression of CKD, particularly rigorous blood pressure control with agents that inhibit the renin-angiotensin system. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical trials evaluating efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Meta-analyses and systematic reviews'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are on a protein restricted diet should be carefully monitored, preferably by a dietitian, with close follow-up every three to six months for adequate caloric intake and evidence of protein malnutrition. We follow the body weight as well as serum albumin, pre-albumin, and cholesterol. More frequent monitoring (ie, monthly) may be necessary in patients with advanced CKD (ie, stages 4 and 5). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/1\">",
"      Meyer TW, Anderson S, Rennke HG, Brenner BM. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 1987; 31:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/2\">",
"      Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 1985; 82:5963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/3\">",
"      Miller PL, Scholey JW, Rennke HG, Meyer TW. Glomerular hypertrophy aggravates epithelial cell injury in nephrotic rats. J Clin Invest 1990; 85:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/4\">",
"      Fukui M, Nakamura T, Ebihara I, et al. Low-protein diet attenuates increased gene expression of platelet-derived growth factor and transforming growth factor-beta in experimental glomerular sclerosis. J Lab Clin Med 1993; 121:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/5\">",
"      Nakamura T, Fukui M, Ebihara I, et al. Low protein diet blunts the rise in glomerular gene expression in focal glomerulosclerosis. Kidney Int 1994; 45:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/6\">",
"      Woods LL. Mechanisms of renal hemodynamic regulation in response to protein feeding. Kidney Int 1993; 44:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/7\">",
"      King AJ, Levey AS. Dietary protein and renal function. J Am Soc Nephrol 1993; 3:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/8\">",
"      Nakamura H, Ito S, Ebe N, Shibata A. Renal effects of different types of protein in healthy volunteer subjects and diabetic patients. Diabetes Care 1993; 16:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/9\">",
"      Kontessis P, Jones S, Dodds R, et al. Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins. Kidney Int 1990; 38:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/10\">",
"      Hirschberg R, Kopple JD. Response of insulin-like growth factor I and renal hemodynamics to a high- and low-protein diet in the rat. J Am Soc Nephrol 1991; 1:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/11\">",
"      Jaffa AA, Vio CP, Silva RH, et al. Evidence for renal kinins as mediators of amino acid-induced hyperperfusion and hyperfiltration in the rat. J Clin Invest 1992; 89:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/12\">",
"      Martinez-Maldonado M, Benabe JE, Wilcox JN, et al. Renal renin, angiotensinogen, and ANG I-converting-enzyme gene expression: influence of dietary protein. Am J Physiol 1993; 264:F981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/13\">",
"      Gao X, Huang L, Grosjean F, et al. Low-protein diet supplemented with ketoacids reduces the severity of renal disease in 5/6 nephrectomized rats: a role for KLF15. Kidney Int 2011; 79:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/14\">",
"      De Miguel C, Lund H, Mattson DL. High dietary protein exacerbates hypertension and renal damage in Dahl SS rats by increasing infiltrating immune cells in the kidney. Hypertension 2011; 57:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/15\">",
"      Mitch WE. Dietary protein restriction in chronic renal failure: nutritional efficacy, compliance, and progression of renal insufficiency. J Am Soc Nephrol 1991; 2:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/16\">",
"      Kopple JD, Levey AS, Greene T, et al. Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 52:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/17\">",
"      Walser M, Mitch WE, Maroni BJ, Kopple JD. Should protein intake be restricted in predialysis patients? Kidney Int 1999; 55:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/18\">",
"      Aparicio M, Chauveau P, De Pr&eacute;cigout V, et al. Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet. J Am Soc Nephrol 2000; 11:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/19\">",
"      Bernhard J, Beaufr&egrave;re B, Laville M, Fouque D. Adaptive response to a low-protein diet in predialysis chronic renal failure patients. J Am Soc Nephrol 2001; 12:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/20\">",
"      KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/21\">",
"      Zeller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991; 324:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/22\">",
"      Walker JD, Bending JJ, Dodds RA, et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989; 2:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/23\">",
"      Ihle BU, Becker GJ, Whitworth JA, et al. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med 1989; 321:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/24\">",
"      Rosman JB, Langer K, Brandl M, et al. Protein-restricted diets in chronic renal failure: a four year follow-up shows limited indications. Kidney Int Suppl 1989; 27:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/25\">",
"      Locatelli F, Alberti D, Graziani G, et al. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet 1991; 337:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/26\">",
"      Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/27\">",
"      Levey AS, Greene T, Sarnak MJ, et al. Effect of dietary protein restriction on the progression of kidney disease: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 2006; 48:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/28\">",
"      Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 1999; 10:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/29\">",
"      D'Amico G, Gentile MG, Fellin G, et al. Effect of dietary protein restriction on the progression of renal failure: a prospective randomized trial. Nephrol Dial Transplant 1994; 9:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/30\">",
"      Pedrini MT, Levey AS, Lau J, et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996; 124:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/31\">",
"      Shah N, Horwitz RI, Concato J. Effects of dietary protein on renal disease. Ann Intern Med 1997; 126:331; author reply 331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/32\">",
"      Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998; 31:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/33\">",
"      Fouque D, Laville M, Boissel JP. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2006; :CD001892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/34\">",
"      Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007; :CD002181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/35\">",
"      Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009; :CD001892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/36\">",
"      Rabbat CG. Review: a low-protein diet delays end-stage renal disease or death in stage 3 to 5 chronic kidney disease. ACP J Club 2006; 145:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/37\">",
"      Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2012; 156:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/38\">",
"      Martinez-Maldonado M, Sattin RW, Sattin RD. Rate of progression of renal disease and low-protein diet. Am J Kidney Dis 1998; 31:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/39\">",
"      Walser M, Hill S, Tomalis EA. Treatment of nephrotic adults with a supplemented, very low-protein diet. Am J Kidney Dis 1996; 28:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/40\">",
"      Walser M, Hill S. Can renal replacement be deferred by a supplemented very low protein diet? J Am Soc Nephrol 1999; 10:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/41\">",
"      Brunori G, Viola BF, Parrinello G, et al. Efficacy and safety of a very-low-protein diet when postponing dialysis in the elderly: a prospective randomized multicenter controlled study. Am J Kidney Dis 2007; 49:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/42\">",
"      Menon V, Kopple JD, Wang X, et al. Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 2009; 53:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/43\">",
"      Ikizler TA. Dietary protein restriction in CKD: the debate continues. Am J Kidney Dis 2009; 53:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/44\">",
"      Williams B, Hattersley J, Layward E, Walls J. Metabolic acidosis and skeletal muscle adaptation to low protein diets in chronic uremia. Kidney Int 1991; 40:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/45\">",
"      Gennari FJ, Hood VL, Greene T, et al. Effect of dietary protein intake on serum total CO2 concentration in chronic kidney disease: Modification of Diet in Renal Disease study findings. Clin J Am Soc Nephrol 2006; 1:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/46\">",
"      Castaneda C, Gordon PL, Uhlin KL, et al. Resistance training to counteract the catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, controlled trial. Ann Intern Med 2001; 135:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/47\">",
"      Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/48\">",
"      Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/49\">",
"      Kaysen GA, Davies RW, Hutchison FN. Effect of dietary protein intake and angiotensin converting enzyme inhibition in Heymann nephritis. Kidney Int Suppl 1989; 27:S154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/50\">",
"      Kaysen GA, Jones H Jr, Martin V, Hutchison FN. A low-protein diet restricts albumin synthesis in nephrotic rats. J Clin Invest 1989; 83:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/51\">",
"      Choi EJ, Bailey J, May RC, et al. Metabolic responses to nephrosis: effect of a low-protein diet. Am J Physiol 1994; 266:F432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?2/45/2777/abstract/52\">",
"      Maroni BJ, Staffeld C, Young VR, et al. Mechanisms permitting nephrotic patients to achieve nitrogen equilibrium with a protein-restricted diet. J Clin Invest 1997; 99:2479.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7178 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.65.66-4367187BB2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2777=[""].join("\n");
var outline_f2_45_2777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF PROTEIN-INDUCED HYPERFILTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hormonal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intrarenal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROTEIN RESTRICTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical trials evaluating efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meta-analyses and systematic reviews",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effects of a very low protein diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monitoring nutritional adequacy in CKD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Estimating protein intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NEPHROTIC SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7178\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7178|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/13/15581\" title=\"figure 1\">",
"      Low protein preserves GFR in DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/31/29181\" title=\"figure 2\">",
"      Low protein diet in ESRD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/40/35469\" title=\"figure 3\">",
"      Low protein diet in CRF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7178|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/16/24844\" title=\"table 1\">",
"      Protein biological value",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35190?source=related_link\">",
"      Calculation of the creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=related_link\">",
"      Chapter 2D: Regulation of GFR and renal plasma flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/27/27066?source=related_link\">",
"      Course and treatment of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=related_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/63/30714?source=related_link\">",
"      Overview of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f2_45_2778="Rosacea papules";
var content_f2_45_2778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67890%7EDERM%2F78747%7EDERM%2F61822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67890%7EDERM%2F78747%7EDERM%2F61822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory papules and pustules are present on the nose and cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rhinophyma in rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Marked distortion of the nose is present in this patient with severe rhinophymatous rosacea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2778=[""].join("\n");
var outline_f2_45_2778=null;
var title_f2_45_2779="Epi issues preven fatal ANA";
var content_f2_45_2779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevention of fatal reactions/important issues in the use of self-injectable epinephrine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Train",
"        </strong>",
"        (teach patients in the ED/physician's office to properly use the devices)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Practice",
"        </strong>",
"        (work monthly with the training devices)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Carry",
"        </strong>",
"        (take the self-injectable epinephrine everywhere and at all times)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Educate/Notify",
"        </strong>",
"        (inform family members, care givers, food providers)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2779=[""].join("\n");
var outline_f2_45_2779=null;
var title_f2_45_2780="Chemo regimens brain tumors";
var content_f2_45_2780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Chemotherapy regimens used for high grade astrocytoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Carmustine",
"       </td>",
"       <td>",
"        150 to 200 mg/m2 day 1",
"       </td>",
"       <td>",
"        Every 6 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        PCV [1]",
"       </td>",
"       <td>",
"        Procarbazine 100 mg/m2 days 1 to 10",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Every 6 to 8 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lomustine 100 mg/m2",
"day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine 1.5 mg/m2 (maximum 2 mg) day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        PCV [2, 3]",
"       </td>",
"       <td>",
"        Procarbazine 60 mg/m2 days 8 to 21",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Every 6 to 8 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lomustine 100 mg/m2",
"day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine 1.5 mg/m2 (maximum 2 mg) days 8 and 29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temozolomide",
"       </td>",
"       <td>",
"        150 to 200 mg/m2 daily for five days",
"       </td>",
"       <td>",
"        Every 4 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Adjuvant temozolomide [4]",
"       </td>",
"       <td>",
"        75 mg/m2 daily during RT",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Up to six cycles of 150 to 200",
"mg/m2 daily for 5 days, every 28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adjuvant temozolomide [5]",
"       </td>",
"       <td>",
"        50 mg/m2 daily during RT only",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. Medical Research Council trial. J Clin Oncol 2001; 19:509.",
"     <br>",
"      2. Levin, VA, et al. Int J Radiat Oncol Biol Phys 1990; 18:321.",
"      <br>",
"       3. van den Bent, MJ, et al. Neurology 1998; 51:1140.",
"       <br>",
"        4. Stupp, R, et al. N Engl J Med 2005; 352:987.",
"        <br>",
"         5. Combs, SE, et al. Proc Am Soc Clin Oncol 2004; 23:114a.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2780=[""].join("\n");
var outline_f2_45_2780=null;
var title_f2_45_2781="Interpretation of the Hepatitis B panel";
var content_f2_45_2781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interpretation of the hepatitis B serologic panel",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"60%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Results",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interpretation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td rowspan=\"3\">",
"        Susceptible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td rowspan=\"3\">",
"        Immune due to natural infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td rowspan=\"3\">",
"        Immune due to hepatitis B vaccination*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td rowspan=\"4\">",
"        Acutely infected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgM anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"       <td rowspan=\"4\">",
"        Chronically infected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgM anti-HBc",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        HBsAg",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td rowspan=\"3\">",
"        Four interpretations possible",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBc",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        anti-HBs",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Antibody response (anti-HBs) can be measured quantitatively or qualitatively. A protective antibody response is reported quantitatively as 10 or more milliinternational units (&gt;=10 mIU/mL) or qualitatively as positive. Post-vaccination testing should be completed 1-2 months after the third vaccine dose for results to be meaningful.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Four interpretations:",
"     <br/>",
"     1. Might be recovering from acute HBV infection.",
"     <br/>",
"     2. Might be distantly immune and test not sensitive enough to detect very low level of anti-HBs in serum.",
"     <br/>",
"     3. Might be susceptible with a false positive anti-HBc.",
"     <br/>",
"     4. Might be undetectable level of HBsAg present in the serum and the person is actually chronically infected.",
"    </div>",
"    <div class=\"reference\">",
"     <p>",
"      Centers for Disease Control and Prevention, Hepatitis B information for health professionals: Interpretation of hepatitis B serologic test results. Available from the CDC website.",
"     </p>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2781=[""].join("\n");
var outline_f2_45_2781=null;
var title_f2_45_2782="Doses asthma control meds kids";
var content_f2_45_2782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual doses for long-term asthma controller medications in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Medication",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dose form",
"      </td>",
"      <td class=\"subtitle1\">",
"       0-4 years",
"      </td>",
"      <td class=\"subtitle1\">",
"       5-11 years",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Systemic corticosteroids",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Methylprednisolone",
"      </td>",
"      <td>",
"       2, 4, 8, 16, 32 mg tablets",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        0.25-2 mg/kg daily in single dose in a.m. or every other day as needed for control",
"       </p>",
"       <p>",
"        Short-course \"burst\": 1-2 mg/kg/day, maximum 30 mg/day for 3-10 days",
"       </p>",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        0.25-2 mg/kg daily in single dose in a.m. or every other day as needed for control",
"       </p>",
"       <p>",
"        Short-course \"burst\": 1-2 mg/kg/day, maximum 60 mg/day for 3-10 days",
"       </p>",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        <strong>",
"         (Applies to all three corticosteroids)",
"        </strong>",
"       </p>",
"       <p>",
"        For long-term treatment of severe persistent asthma, administer single dose in a.m. either daily or on alternate days (alternate-day therapy may produce less adrenal suppression)",
"       </p>",
"       <p>",
"        Short courses or \"bursts\" are effective for establishing control when initiating therapy or during a period of gradual deterioration",
"       </p>",
"       <p>",
"        There is no evidence that tapering the dose following improvement in symptom control and pulmonary function prevents relapse",
"       </p>",
"       <p>",
"        Patients receiving the lower dose (1 mg/kg/day) experience fewer behavioral side effects (Kayani and Shannon 2002), and it appears to be equally efficacious (Rachelefsky 2003)",
"       </p>",
"       <p>",
"        For patients unable to tolerate the liquid preparations, dexamethasone syrup at 0.4 mg/kg/day may be an alternative. Studies are limited, however, and the longer duration of activity increases the risk of adrenal suppression (Hendeles 2003).",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Prednisolone",
"      </td>",
"      <td>",
"       5 mg tablets, 5 mg/5 cc, 15 mg/5 cc",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Prednisone",
"      </td>",
"      <td>",
"       1, 2.5, 5, 10, 20, 50 mg tablets; 5 mg/cc, 5 mg/5 cc",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Combined medication",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fluticasone/salmeterol",
"      </td>",
"      <td>",
"       DPI 100 mcg/50 mcg",
"      </td>",
"      <td>",
"       Safety and efficacy not established in children &lt;4 years",
"      </td>",
"      <td>",
"       1 inhalation twice a day",
"      </td>",
"      <td>",
"       <p>",
"        There have been no clinical trials in children &lt;4 years of age",
"       </p>",
"       <p>",
"        Most children &lt;4 years of age cannot provide sufficient inspiratory flow for adequate lung delivery",
"       </p>",
"       <p>",
"        Do not blow into inhaler after dose is activated",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Budesonide/formoterol",
"      </td>",
"      <td>",
"       HFA MDI 80 mcg/4.5 mcg",
"      </td>",
"      <td>",
"       Safety and efficacy not established",
"      </td>",
"      <td>",
"       2 puffs twice a day",
"      </td>",
"      <td>",
"       <p>",
"        There have been no clinical trials in children &lt;4 years of age",
"       </p>",
"       <p>",
"        Currently approved for use in youths &ge;12. Dose for children 5-12 years of age based on clinical trials using DPI with slightly different delivery characteristics (Pohunek et al. 2006; Tal et al. 2002; Zimmerman et al. 2004).",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Cromolyn/nedocromil",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       Cromolyn",
"      </td>",
"      <td>",
"       MDI 0.8 mg/puff",
"      </td>",
"      <td>",
"       Safety and efficacy not established",
"      </td>",
"      <td>",
"       2 puffs four times a day",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        4-6 week trial may be needed to determine maximum benefit.",
"       </p>",
"       <p>",
"        Dose by MDI may be inadequate to affect hyperresponsiveness",
"       </p>",
"       <p>",
"        One dose before exercise or allergen exposure provides effective prophylaxis for 1-2 hours. Not as effective as inhaled beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonists for EIB",
"       </p>",
"       <p>",
"        Once control is achieved, the frequency of dosing may be reduced",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nebulizer 20 mg/ampule",
"      </td>",
"      <td>",
"       <p>",
"        1 ampule four times a day",
"       </p>",
"       <p>",
"        Safety and efficacy not established &lt;2 years",
"       </p>",
"      </td>",
"      <td>",
"       1 ampule four times a day",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nedocromil",
"      </td>",
"      <td>",
"       MDI 1.75 mg/puff",
"      </td>",
"      <td>",
"       Safety and efficacy not established &lt;6 years",
"      </td>",
"      <td>",
"       2 puffs four times a day",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Leukotriene receptor antagonists (LTRAs)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Montelukast",
"      </td>",
"      <td>",
"       <p>",
"        4 mg or 5 mg chewable tablet",
"       </p>",
"       <p>",
"        4 mg granule packets",
"       </p>",
"      </td>",
"      <td>",
"       4 mg at bedtime (1-5 years of age)",
"      </td>",
"      <td>",
"       5 mg at bedtime (6-14 years of age)",
"      </td>",
"      <td rowspan=\"2\">",
"       <p>",
"        Montelukast exhibits a flat dose response curve",
"       </p>",
"       <p>",
"        No more efficacious than placebo in infants 6-24 months (van Adelsberg et al. 2005)",
"       </p>",
"       <p>",
"        For zafirlukast, administration with meals decreases bioavailability; take at least 1 hour before or 2 hours after meals",
"       </p>",
"       <p>",
"        Monitor for signs and symptoms of hepatic dysfunction",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Zafirlukast",
"      </td>",
"      <td>",
"       10 mg tablet",
"      </td>",
"      <td>",
"       Safety and efficacy not established",
"      </td>",
"      <td>",
"       10 mg twice a day (7-11 years of age)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Methylxanthines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"3\">",
"       Theophylline",
"      </td>",
"      <td rowspan=\"3\">",
"       Liquids, sustained-release tablets, and capsules",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Starting dose 10 mg/kg/day; usual maximum:",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Starting dose 10 mg/kg/day; usual maximum:",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        Adjust dose to achieve serum concentration of 5-15 mcg/mL at steady-state (at least 48 hours on same dose)",
"       </p>",
"       <p>",
"        Due to wide interpatient variability in theophylline metabolic clearance, routine serum theophylline level monitoring is essential",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &lt;1 year of age: 0.2 (age in weeks) + 5 = mg/kg/day",
"      </td>",
"      <td class=\"sublist1\" rowspan=\"2\">",
"       16 mg/kg/day",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &ge;1 year of age: 16 mg/kg/day",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DPI: dry powder inhaler; EIB: exercise-induced bronchospasm; HFA: hydrofluoroalkane (inhaler propellant); MDI: metered dose inhaler.",
"     <br>",
"      * Doses are provided for those products that have been approved by the U.S. Food and Drug Administration or have sufficient clinical trial safety and efficacy data in the appropriate age ranges to support their use.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2782=[""].join("\n");
var outline_f2_45_2782=null;
var title_f2_45_2783="Chorionic villi1";
var content_f2_45_2783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chorionic villi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 166px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    One method of distinguishing placenta from organized clot is to rinse with water and then float the tissue in a dish of water, preferably with a good light source underneath. Villi have a frond-like appearance, which has been described as similar to seaweed floating in the ocean",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Errol R Norwitz, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f2_45_2783=[""].join("\n");
var outline_f2_45_2783=null;
